Forschung / Studien

Unsere Forschung – Ihre Chance

Die Studienzentrale der Frauenklinik bietet Patientinnen die Möglichkeit, im Rahmen ihrer Behandlung an ausgewählten klinischen Studien teilzunehmen. Insbesondere im Bereich der Brustkrebsforschung sind in den letzten Jahren große Fortschritte erzielt worden. Von diesen Ergebnissen können unsere Patientinnen schon heute durch eine Studienteilnahme profitieren. Als eine der größten Universitätsfrauenkliniken Deutschlands führen wir aber auch Studien im gesamten Bereich der Gynäkologie durch, wie etwa auch in der Geburtshilfe, in der Urogynäkologie, der Pränataldiagnostik und anderen Bereichen.

Neben der Durchführung klinischer Studien leisten wir als forschende Universitätsklinik auch selbst aktiv einen Beitrag zur wissenschaftlichen Grundlagenforschung. An unserer Klinik forschen etablierte Arbeitsgruppen. Unsere wissenschaftlichen Schwerpunkte liegen dabei besonders auf der Untersuchung zirkulierender Tumorzellen (DETECT-Studien), der Gefäßneubildung bösartiger Tumore, bei der grundlagenwissenschaftlichen sowie anwendungsbezogenen Untersuchung von DNA-Reparaturmechanismen sowie der Untersuchung frühkindlicher Faktoren auf die spätere Entwicklung.

Studienzentrale & Studien

Arbeitsgruppen & Labore

Sektion Gynäkologische Onkologie

Details

Labor für Molekulargenetik und Molekularbiologie

Details

Publikationen der Frauenklinik

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28(8): 1700-1712 (Impact(2016)=11.855). Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 , André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B

Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al. Ann Oncol. 2017; (Impact(2016)=11.855). Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, Panel Members of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 , André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B

Ten-year Results of Intense Dose-dense chemotherapy show superior survival compared to a conventional schedule in High-risk Primary Breast Cancer: Final results of AGO Phase III iddEPC trial. Ann Oncol. 2017; (Impact(2016)=11.855). Möbus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Konecny GE, Untch M, Kurbacher C, AGO Breast Study Group (AGO-B) , Kahlert S, Hauser N, Marmé F, Kiesel L, Wallwiener D, Rautenberg B, Hofmann R, Barinoff J, Stickeler E, Eidtmann H, Müller V, Emons G, Mallmann P, Hackenberg R, Hielscher C, Räber G, Sommer H, Schmidt-Rhode P, Jahns B, von der Assen A, Dietterle S, Kaufmann M, Strunk C, Goebel R, Paepke S, Paulenz A, Junker-Stein A, Rhein U, Bremer K, Bauer W, Hohlweg-Majert P, Kramer D, Meerpohl HG, Diedrich K, Dall P, Kölbl H, Brückner B, Gros R, Stehle H, Lobodasch K, Dinkelacker T, Klöpper E, Karg C, Stibora M, Weise W, Melchert F, Mohrmann S, Klatt C, Schmidt M, Glados M, Mickan H, Pollmanns A, Beck T, Schröder W, Klingemann H, Köhler G, Freier W, Graßhoff ST, Söling U, Keil E, Höß C, Kullmer U, Niesel A, Bodenstein H, Bartzke G, Schlotter CM, Wiest W, Ernst W, Brudler O, Heinrich B, Hackmann J, Niedner W, Hoffmann G, Knapp W, Dresemann G, Karl C, Klemm FJ, Schliesser GC, Butterwegge M, Meden H, Kirschbaum M, Schwenzer T, Voigt HJ, Weiß U, Önder G, Langer W, Glaubitz M, Beha M, Coumbos A, Ko Y, Deuker JU, Prümmer O, Wagner U, Kohlstedt A, Schreiber P, Jovanovic V, Drzewiecki K, Guba H, Seipt H, Stauch M, Maintz C, Morenz B

German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. Ann Oncol. 2017;28(8): 1803-1810 (Impact(2016)=11.855). Möbus V, von Minckwitz G, Jackisch C, Lück HJ, Schneeweiss A, Tesch H, Elling D, Harbeck N, Conrad B, Fehm T, Huober J, Müller V, Bauerfeind I, du Bois A, Loibl S, Nekljudova V, Untch M, Thomssen C, German Breast Group (GBG), the AGO Breast Study Group (AGO-B) and NOGGO Study Groups

Patient and tumor characteristics and their influence on early therapy persistence with letrozole in postmenopausal patients with early breast cancer. Ann Oncol. 2017; (Impact(2016)=11.855). Nabieva N, Kellner S, Fehm T, Häberle L, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesselt T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Brucker SY, Kümmel S, Beckmann MW, Wallwiener D, Hadji P, Fasching PA

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol. 2017;28(11): 2899 (Impact(2016)=11.855). Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W

Surgery of Anterior Skull Base Lesions in Children. Ann Otol Rhinol Laryngol. 2017;126(3): 245-253 (Impact(2016)=1.384). Hoffmann TK, Scheithauer MO, Sommer F, Lindemann J, Haberl EJ, Friebe-Hoffmann U, Theodoraki MN

Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study. Ann Surg Oncol. 2017;24(5): 1314-1321 (Impact(2016)=4.041). Klapdor R, Hillemanns P, Wölber L, Jückstock J, Hilpert F, de Gregorio N, Iborra S, Sehouli J, Habermann A, Fürst ST, Strauß HG, Baumann K, Thiel F, Mustea A, Meier W, Harter P, Wimberger P, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, Jäger M, Mahner S

Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. Anticancer Res. 2017;37(6): 3117-3128 (Impact(2016)=1.937). Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer EF, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Müller V

Pattern of metastatic spread and subcategories of breast cancer. Arch Gynecol Obstet. 2017;295(1): 211-223 (Impact(2016)=2.09). Bartmann C, Wischnewsky M, Stüber T, Stein R, Krockenberger M, Häusler S, Janni W, Kreienberg R, Blettner M, Schwentner L, Wöckel A, Diessner J

Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network. Arch Gynecol Obstet. 2017;295(5): 1239-1245 (Impact(2016)=2.09). Fremd C, Hack CC, Schneeweiss A, Rauch G, Wallwiener D, Brucker SY, Taran FA, Hartkopf A, Overkamp F, Tesch H, Fehm T, Hadji P, Janni W, Lüftner D, Lux MP, Müller V, Ettl J, Belleville E, Sohn C, Schuetz F, Beckmann MM, Fasching PA, Wallwiener M

Value of endometrial thickness assessed by transvaginal ultrasound for the prediction of endometrial cancer in patients with postmenopausal bleeding. Arch Gynecol Obstet. 2017;296(2): 319-326 (Impact(2016)=2.09). Schramm A, Ebner F, Bauer E, Janni W, Friebe-Hoffmann U, Pellegrino M, De Gregorio N, Friedl TWP

Alterations of hair cortisol and dehydroepiandrosterone in mother-infant-dyads with maternal childhood maltreatment. BMC Psychiatry. 2017;17(1): 213 (Impact(2016)=2.613). Schury K, Koenig AM, Isele D, Hulbert AL, Krause S, Umlauft M, Kolassa S, Ziegenhain U, Karabatsiakis A, Reister F, Guendel H, Fegert JM, Kolassa IT

Factors influencing the development of visceral metastasis of breast cancer: A retrospective multi-center study. Breast. 2017;31: 66-75 (Impact(2016)=2.801). Bartmann C, Diessner J, Blettner M, Häusler S, Janni W, Kreienberg R, Krockenberger M, Schwentner L, Stein R, Stüber T, Wöckel A, Wischnewsky M

pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. Breast. 2017;32: 73-78 (Impact(2016)=2.801). Reinisch M, Huober J, von Minckwitz G, Blohmer JU, Denkert C, Hanusch C, Jackisch C, Kümmel S, Schneeweiss A, Rhiem K, Lederer B, Untch M, Nekljudova V V, Loibl S

Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trial. Breast. 2017;31: 202-207 (Impact(2016)=2.801). Schwentner L, Helms G, Nekljudova V, Ataseven B, Bauerfeind I, Ditsch N, Fehm T, Fleige B, Hauschild M, Heil J, Kümmel S, Lebeau A, Schmatloch S, Schrenk P, Staebler A, Loibl S, Untch M, Von Minckwitz G, Liedtke C, Kühn T

Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study. Breast. 2017;35: 130-135 (Impact(2016)=2.801). Trapp E, Steidl J, Rack B, Kupka MS, Andergassen U, Jückstock J, Kurt A, Vilsmaier T, de Gregorio A, de Gregorio N, Tzschaschel M, Lato C, Polasik A, Tesch H, Schneeweiss A, Beckmann MW, Fasching PA, Janni W, Müller V

Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial. Breast Cancer. 2017;24(2): 319-325 (Impact(2016)=1.572). Eichler M, Singer S, Janni W, Harbeck N, Rack B, Augustin D, Wischnik A, Kiechle M, Ettl J, Scholz C, Fink V, Schwentner L

Which patient- and physician-related factors are associated with guideline adherent initiation of adjuvant endocrine therapy? Results of the prospective multi-centre cohort study BRENDA II. Breast Cancer. 2017;24(2): 281-287 (Impact(2016)=1.572). Stüber T, van Ewijk R, Diessner J, Kühn T, Flock F, Felberbaum R, Blettner M, Kreienberg R, Janni W, Wöckel A, Singer S, Schwentner L

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. Breast Cancer Res Treat. 2017;161(1): 63-72 (Impact(2016)=3.626). Harbeck N, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, Otremba BJ, Waldenmaier D, Dorn J, Warm M, Scholz M, Untch M, de Wit M, Barinoff J, Lück HJ, Harter P, Augustin D, Harnett P, Beckmann MW, Al-Batran SE, PELICAN Investigators

3D conformal radiotherapy is not associated with the long-term cardiac mortality in breast cancer patients: a retrospective cohort study in Germany (PASSOS-Heart Study). Breast Cancer Res Treat. 2017;161(1): 143-152 (Impact(2016)=3.626). Merzenich H, Bartkowiak D, Schmidberger H, Schmidt M, Schwentner L, Wiegel T, Woeckel A, Wollschläger D, Blettner M

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Breast Cancer Res Treat. 2017; (Impact(2016)=3.626). Ponde N, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H, Zardavas D, Di Cosimo S, Baselga J, Huober J, Izquierdo M, Fumagalli D, Bozovic-Spasojevic I, Maetens M, Harbeck N, Pusztai L, Berghorn M, Im YH, Borrego MR, Chen DR, Rodeheffer R, Piccart M, Suter T, de Azambuja E

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat. 2017; (Impact(2016)=3.626). Sonke GS, Hart LL, Campone M, Erdkamp F, Janni W, Verma S, Villanueva C, Jakobsen E, Alba E, Wist E, Favret AM, Bachelot T, Hegg R, Wheatley-Price P, Souami F, Sutradhar S, Miller M, Germa C, Burris HA

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2017; (Impact(2016)=3.626). Villegas SL, Darb-Esfahani S, von Minckwitz G, Huober J, Weber K, Marmé F, Furlanetto J, Schem C, Pfitzner BM, Lederer B, Engels K, Kümmel S, Müller V, Mehta K, Denkert C, Loibl S

Self-reported long-term cardiac morbidity in breast cancer patients: a retrospective cohort study in Germany (PASSOS Heart Study). Breast Cancer Res Treat. 2017;163(3): 595-604 (Impact(2016)=3.626). Wollschläger D, Merzenich H, Schwentner L, Janni W, Wiegel T, Bartkowiak D, Wöckel A, Schmidt M, Schmidberger H, Blettner M

Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Res Treat. 2017; (Impact(2016)=3.626). van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, Marmé F, Stickeler E, Jackisch C, Hanusch C, Huober J, Fasching PA, Blohmer JU, Kümmel S, Müller V, Schneeweiss A, Untch M, von Minckwitz G, Weber KE, Loibl S

CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer. Breast Care (Basel). 2017;12(2): 118-120 (Impact(2016)=1.553). Ettl J, Huober J, Lüftner D, Marmé F, Würstlein R

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2017. Breast Care (Basel). 2017;12(3): 172-183 (Impact(2016)=1.553, Typ=Article; Journal Article). Liedtke C, Thill M, Jackisch C, Thomssen C, Müller V, Janni W, AGO Breast Committee*

San Antonio 2016: Progress on the Long Way to Individualized Treatment of Breast Cancer. Breast Care (Basel). 2017;12(1): 54-58 (Impact(2016)=1.553). Müller V, Gluz O, Pierga JY, Thill M, Rack B, Witzel I

AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2017. Breast Care (Basel). 2017;12(3): 184-191 (Impact(2016)=1.553). Thill M, Liedtke C, Solomayer EF, Müller V, Janni W, Schmidt M, AGO Breast Committee*

Is extracapsular nodal extension in sentinel nodes a predictor for nonsentinel metastasis and is there an impact on survival parameters?-A retrospective single center cohort study with 324 patients. Breast J. 2017; (Impact(2016)=2.297). Schwentner L, Dayan D, Wöckel A, Janni W, Kreienberg R, Blettner M, Wollschläger D

Comorbidity-dependent adherence to guidelines and survival in breast cancer-Is there a role for guideline adherence in comorbid breast cancer patients? A retrospective cohort study with 2137 patients. Breast J. 2017; (Impact(2016)=2.297). Wollschläger D, Meng X, Wöckel A, Janni W, Kreienberg R, Blettner M, Schwentner L

ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage.
Cancer Res. 2017;77(20): 5576-5590 (Impact(2016)=9.122). Perkhofer L, Schmitt A, Romero Carrasco MC, Ihle M, Hampp S, Ruess DA, Hessmann E, Russell R, Lechel A, Azoitei N, Lin Q, Liebau S, Hohwieler M, Bohnenberger H, Lesina M, Algül H, Gieldon L, Schröck E, Gaedcke J, Wagner M, Wiesmüller L, Sipos B, Seufferlein T, Reinhardt HC, Frappart PO, Kleger A

The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial. Clin Breast Cancer. 2017;17(2): 100-106 (Impact(2016)=2.816). Leinert E, Singer S, Janni W, Harbeck N, Weissenbacher T, Rack B, Augustin D, Wischnik A, Kiechle M, Ettl J, Fink V, Schwentner L, Eichler M

Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. Clin Breast Cancer. 2017;17(4): 279-285 (Impact(2016)=2.816). Schramm A, Schochter F, Friedl TWP, de Gregorio N, Andergassen U, Alunni-Fabbroni M, Trapp E, Jaeger B, Heinrich G, Camara O, Decker T, Ober A, Mahner S, Fehm TN, Pantel K, Fasching PA, Schneeweiss A, Janni W, Rack BK, SUCCESS Study Group

HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res. 2017;23(15): 4323-4334 (Impact(2016)=9.619). Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL

Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Clin Cancer Res. 2017;23(18): 5384-5393 (Impact(2016)=9.619). Riethdorf S, Müller V, Loibl S, Nekljudova V, Weber K, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Schem C, von Minckwitz G, Untch M, Pantel K

Mosaic genome-wide maternal isodiploidy: an extreme form of imprinting disorder presenting as prenatal diagnostic challenge. Clin Epigenetics. 2017;9: 111 (Impact(2016)=4.987). Bens S, Luedeke M, Richter T, Graf M, Kolarova J, Barbi G, Lato K, Barth TF, Siebert R

Advances in the management of HER2-positive early breast cancer. Crit Rev Oncol Hematol. 2017;119: 113-122 (Impact(2016)=4.971). Baselga J, Coleman RE, Cortés J, Janni W

Feasibility and effects of a combined adjuvant high-intensity interval/strength training in breast cancer patients: a single-center pilot study. Disabil Rehabil. 2017;: 1-8 (Impact(2016)=1.804). Schulz SVW, Laszlo R, Otto S, Prokopchuk D, Schumann U, Ebner F, Huober J, Steinacker JM

Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). Eur J Cancer. 2017;84: 1-8 (Impact(2016)=6.029, Typ=Article; Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't; Comparative Study). Kümmel S, Paepke S, Huober J, Schem C, Untch M, Blohmer JU, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Jackisch C, Schneeweiss A, Denkert C, Engels K, Klare P, Fasching PA, von Minckwitz G, Burchardi N, Loibl S

Peripheral Immunological Cells in Pregnant Women and their Change during Diabetes. Exp Clin Endocrinol Diabetes. 2017;125(10): 677-683 (Impact(2016)=1.685). Friebe-Hoffmann U, Antony L, Kruessel JS, Pawlowski B, Hoffmann TK

Slit2/Robo4 Signaling: Potential Role of a VEGF-Antagonist Pathway to Regulate Luteal Permeability. Geburtshilfe Frauenheilkd. 2017;77(1): 73-80 (Impact(2016)=1.07). Bekes I, Haunerdinger V, Sauter R, Holzheu I, Janni W, Wöckel A, Wulff C

Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study. Geburtshilfe Frauenheilkd. 2017;77(6): 651-659 (Impact(2016)=1.07). Hein A, Rack B, Li L, Ekici AB, Reis A, Lux MP, Cunningham JM, Rübner M, Fridley BL, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L, Fasching PA, Häberle L

Update Breast Cancer 2017 - Implementation of Novel Therapies. Geburtshilfe Frauenheilkd. 2017;77(12): 1281-1290 (Impact(2016)=1.07). Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Ettl J, Huober JB, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Fasching PA

Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer? Geburtshilfe Frauenheilkd. 2017;77(12): 1291-1298 (Impact(2016)=1.07). Polasik A, Tzschaschel M, Schochter F, de Gregorio A, Friedl TWP, Rack B, Hartkopf A, Fasching PA, Schneeweiss A, Müller V, Huober J, Janni W, Fehm T

Discourse Is Research at German University Clinics still desirable, possible and effective? - Summary of the Discussion Forum at the 61st DGGG-Congress 2016 in Stuttgart. Geburtshilfe Frauenheilkd. 2017;77(6): 603-604 (Impact(2016)=1.07). Puppe J, Schott S, Eismann S, Tzschaschel M, Rody A, Wockel A, Lermann J, Gabriel L, Beckmann MW, Gass P

Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). Geburtshilfe Frauenheilkd. 2017;77(6): 633-644 (Impact(2016)=1.07). Untch M, Huober J, Jackisch C, Schneeweiss A, Brucker SY, Dall P, Denkert C, Fasching PA, Fehm T, Gerber B, Janni W, Kühn T, Lüftner D, Möbus V, Müller V, Rody A, Sinn P, Thill M, Thomssen C, Harbeck N, Liedtke C

Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry. Geburtshilfe Frauenheilkd. 2017;77(8): 870-878 (Impact(2016)=1.07). Wallwiener M, Heindl F, Brucker SY, Taran FA, Hartkopf A, Overkamp F, Kolberg HC, Hadji P, Tesch H, Ettl J, Lux MP, Rauh C, Blum S, Nabieva N, Brodkorb TF, Faschingbauer C, Langemann H, Schulmeyer C, Volz B, Rübner M, Lüftner D, Müller V, Belleville E, Janni W, Fehm TN, Wallwiener D, Ganslandt T, Beckmann MW, Schneeweiss A, Fasching PA, Gass P

Methylation patterns in serum DNA for early identification of disseminated breast cancer. Genome Med. 2017;9(1): 115 (Impact(2016)=7.071). Widschwendter M, Evans I, Jones A, Ghazali S, Reisel D, Ryan A, Gentry-Maharaj A, Zikan M, Cibula D, Eichner J, Alunni-Fabbroni M, Koch J, Janni WJ, Paprotka T, Wittenberger T, Menon U, Wahl B, Rack B, Lempiäinen H

Comparison of Fetomaternal Outcome between 47 Deliveries Following Successful External Cephalic Version for Breech Presentation and 7456 Deliveries Following Spontaneous Cephalic Presentation. Gynecol Obstet Invest. 2017; (Impact(2016)=1.415). de Gregorio N, Friedl T, Schramm A, Reister F, Janni W, Ebner F

Quercetin alters the DNA damage response in human hematopoietic stem and progenitor cells via TopoII- and PI3K-dependent mechanisms synergizing in leukemogenic rearrangements. Int J Cancer. 2017;140(4): 864-876 (Impact(2016)=6.513). Biechonski S, Gourevich D, Rall M, Aqaqe N, Yassin M, Zipin-Roitman A, Trakhtenbrot L, Olender L, Raz Y, Jaffa AJ, Grisaru D, Wiesmuller L, Elad D, Milyavsky M

Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol. 2017; (Impact(2016)=7.738). Ong JS, ..., Wang-Gohrke S, ...

Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. Integr Cancer Ther. 2017;16(2): 165-175 (Impact(2016)=1.923). Hack CC, Fasching PA, Fehm T, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesslet T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Hadji P, Brucker SY, Wallwiener D, Kümmel S, Beckmann MW, Paepke D

Personalized axillary dissection: the number of excised lymph nodes of nodal-positive breast cancer patients has no significant impact on relapse-free and overall survival. J Cancer Res Clin Oncol. 2017;143(9): 1823-1831 (Impact(2016)=3.503). Ebner F, Wockel A, Janni W, Kreienberg R, Schwentner L, Wischnewsky M

Personalized axillary dissection: the number of excised lymph nodes of nodal-positive breast cancer patients has no significant impact on relapse-free and overall survival. J Cancer Res Clin Oncol. 2017; (Impact(2016)=3.503). Ebner F, Wöckel A, Janni W, Kreienberg R, Schwentner L, Wischnewsky M

A Biallelic Mutation in the Homologous Recombination Repair Gene SPIDR Is Associated With Human Gonadal Dysgenesis. J Clin Endocrinol Metab. 2017;102(2): 681-688 (Impact(2016)=5.455). Smirin-Yosef P, Zuckerman-Levin N, Tzur S, Granot Y, Cohen L, Sachsenweger J, Borck G, Lagovsky I, Salmon-Divon M, Wiesmüller L, Basel-Vanagaite L

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32): 3638-3646 (Impact(2016)=24.008). Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A

Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol. 2017;35(20): 2240-2250 (Impact(2016)=24.008). Lecarpentier J, ..., Wang-Gohrke S, ...

Naïve T cells are activated by autologous HCMV-infected endothelial cells through NKG2D and can control HCMV transmission in vitro. J Gen Virol. 2017; (Impact(2016)=2.838). Subramanian N, Wu Z, Reister F, Sampaio KL, Frascaroli G, Cicin-Sain L, Mertens T

Naive T cells are activated by autologous HCMV-infected endothelial cells through NKG2D and can control HCMV transmission in vitro. J Gen Virol. 2017;98(12): 3068-3085 (Impact(2016)=2.838). Subramanian N, Wu ZG, Reister F, Sampaio KL, Frascaroli G, Cicin-Sain L, Mertens T

Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial. J Geriatr Oncol. 2017; (Impact(2016)=2.852). Honecker F, Harbeck N, Schnabel C, Wedding U, Waldenmaier D, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, Otremba B, Dorn J, Warm M, Al-Batran SE, de Wit M, PELICAN investigators

Evaluation of simparteam - a needs-orientated team training format for obstetrics and neonatology. J Perinat Med. 2017;45(3): 333-341 (Impact(2016)=1.577). Zech A, Gross B, Jasper-Birzele C, Jeschke K, Kieber T, Lauterberg J, Lazarovici M, Prückner S, Rall M, Reddersen S, Sandmeyer B, Scholz C, Stricker E, Urban B, Zobel A, Singer I

To clip or not to clip the breast tumor bed? A retrospective look at the geographic miss index and normal tissue index of 110 patients with breast cancer. J Turk Ger Gynecol Assoc. 2017;18(2): 67-71 (Impact: liegt nicht vor). Ebner F, de Gregorio N, Rempen A, Mohr P, de Gregorio A, Wöckel A, Janni W, Witucki G

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol. 2017;3(10): 1378-1385 (Impact(2016)=16.559). Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, Paepke S, Gerber B, Kümmel S, Schem C, Neidhardt G, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Schmutzler RK

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. Jama Oncology. 2017;3(2): 227-234 (Impact: liegt nicht vor). Fumagalli D, Venet D, Ignatiadis M, Azim HA, Maetens M, Rothe F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Pena L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(12): 1688-1700 (Impact(2016)=33.9. Martin M, ..., Janni W, ..., Charif M

[Unilateral Supraclavicular Swelling during Pregnancy]. Laryngorhinootologie. 2017;96(5): 312-313 (Impact(2016)=0.732). Hahn J, Friebe-Hoffmann U, Bischof F

Phenotypic Analysis of ATM Protein Kinase in DNA Double-Strand Break Formation and Repair. Methods Mol Biol. 2017;1599: 317-334 (Impact: liegt nicht vor). Mian E, Wiesmüller L

LKB1 pro-oncogenic activity triggers cell survival in circulating tumor cells. Mol Oncol. 2017;11(11): 1508-1526 (Impact(2016)=5.314). Trapp EK, Majunke L, Zill B, Sommer H, Andergassen U, Koch J, Harbeck N, Mahner S, Friedl TWP, Janni W, Rack B, Alunni-Fabbroni M

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017;377(19): 1836-1846 (Impact(2016)=72.406). Pan H, ..., Janni W, ...

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377(2): 122-131 (Impact(2016)=72.406). von Minckwitz G, ..., Janni W, ...

Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women. Nat Commun. 2017;8(1): 1632 (Impact(2016)=12.124). Kadalayil L, Khan S, Nevanlinna H, Fasching PA, Couch FJ, Hopper JL, Liu J, Maishman T, Durcan L, Gerty S, Blomqvist C, Rack B, Janni W, Collins A, Eccles D, Tapper W

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017;49(12): 1767-1778 (Impact(2016)=27.959). Milne RL, ..., Janni W, ...

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017;49(5): 680-691 (Impact(2016)=27.959). Phelan CM, ..., Wang-Gohrke S, ...

Association analysis identifies 65 new breast cancer risk loci. Nature. 2017;551(7678): 92-94 (Impact(2016)=40.137). Michailidou K, ..., Janni W, ..., Rack B, ..., Wang-Gohrke S, ...

The C-terminal domain of p53 orchestrates the interplay between non-covalent and covalent poly(ADP-ribosyl)ation of p53 by PARP1. Nucleic Acids Res. 2017; (Impact(2016)=10.162). Fischbach A, Krüger A, Hampp S, Assmann G, Rank L, Hufnagel M, Stöckl MT, Fischer JMF, Veith S, Rossatti P, Ganz M, Ferrando-May E, Hartwig A, Hauser K, Wiesmüller L, Bürkle A, Mangerich A

Response Evaluation in Head and Neck Oncology: Definition and Prediction. ORL J Otorhinolaryngol Relat Spec. 2017;79(1-2): 14-23 (Impact(2016)=1.055). Hoffmann TK, Schuler PJ, Laban S, Grässlin R, Beer M, Beer AJ, Friebe-Hoffmann U, Bullinger L, Möller P, Wiegel T

Are There Breast Cancer Patients with Node-Negative Small Tumours, Who Do Not Benefit from Adjuvant Systemic Therapy? Oncology. 2017;92(6): 317-324 (Impact(2016)=2.262). Stüber T, Novopashenny I, Diessner J, Bartmann C, Stein R, Krockenberger M, Häusler S, Janni W, Kreienberg R, Blettner M, Wöckel A, Wischnewsky M

Increased single-strand annealing rather than non-homologous end-joining predicts hereditary ovarian carcinoma. Oncotarget. 2017;8(58): 98660-98676 (Impact(2016)=5.168). Deniz M, Romashova T, Kostezka S, Faul A, Gundelach T, Moreno-Villanueva M, Janni W, Friedl TWP, Wiesmüller L

Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity. Oncotarget. 2017;8(44): 78133-78143 (Impact(2016)=5.168). Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L

Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. Oncotarget. 2017;8(3): 3811-3825 (Impact(2016)=5.168). Kiechl S, Schramek D, Widschwendter M, Fourkala EO, Zaikin A, Jones A, Jaeger B, Rack B, Janni W, Scholz C, Willeit J, Weger S, Mayr A, Teschendorff A, Rosenthal A, Fraser L, Philpott S, Dubeau L, Keshtgar M, Roylance R, Jacobs IJ, Menon U, Schett G, Penninger JM

The 15th St. Gallen International Breast Cancer Conference 2017: treatment of early breast cancer. Praxis-relevant statements of German specialists. Onkologe. 2017;23(8): 666-677 (Impact(2016)=0.087). Schneeweiss A, Huober J, Jackisch C, Liedtke C, Harbeck N, Untch M

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS ONE. 2017;12(10): e0186043 (Impact(2016)=2.806). Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Kimmig R, Kast K, Sehouli J, Baumann K, Jackisch C, Park-Simon TW, Hanker L, Kröber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunhöffer T, Krockenberger M, Brucker SY, Nürnberg P, Thiele H, Altmüller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R

The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial. PLoS ONE. 2017;12(6): e0173593 (Impact(2016)=2.806). Jaeger BAS, Neugebauer J, Andergassen U, Melcher C, Schochter F, Mouarrawy D, Ziemendorff G, Clemens M, V Abel E, Heinrich G, Schueller K, Schneeweiss A, Fasching P, Beckmann MW, Scholz C, Friedl TWP, Friese K, Pantel K, Fehm T, Janni W, Rack B

Predictors of the course of quality of life during therapy in women with primary breast cancer. Qual Life Res. 2017;26(8): 2201-2208 (Impact(2016)=2.344). Wöckel A, Schwentner L, Krockenberger M, Kreienberg R, Janni W, Wischnewsky M, Thorsten K, Felix F, Riccardo F, Blettner M, Singer S

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer. Sci Rep. 2017;7(1): 17307 (Impact(2016)=4.259, Typ=Article; Journal Article). Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer EF, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Müller V

Gestational Weight Gain and Fetal-Maternal Adiponectin, Leptin, and CRP: results of two birth cohorts studies. Sci Rep. 2017;7: 41847 (Impact(2016)=4.259). Logan CA, Bornemann R, Koenig W, Reister F, Walter V, Fantuzzi G, Weyermann M, Brenner H, Genuneit J, Rothenbacher D

DEK is required for homologous recombination repair of DNA breaks. Sci Rep. 2017;7: 44662 (Impact(2016)=4.259). Smith EA, Gole B, Willis NA, Soria R, Starnes LM, Krumpelbeck EF, Jegga AG, Ali AM, Guo H, Meetei AR, Andreassen PR, Kappes F, Vinnedge LM, Daniel JA, Scully R, Wiesmüller L, Wells SI

[Pregnancy Rhinitis - an Update]. Z Geburtshilfe Neonatol. 2017;221(2): 59-66 (Impact(2016)=0.476). Friebe-Hoffmann U, Lindemann J

[EXIT - A Possible Intervention for New- and Earlyborn Babies with Severe Hydrops Fetalis and Hydrothoraces on Both Sides]. Z Geburtshilfe Neonatol. 2017;221(6): 286-290 (Impact(2016)=0.476). Koch S, Essers J, Beringer O, Reister F, Hummler H, Moewes A

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Ann Oncol. 2016;27(6): 1035-40 (Impact(2016)=11.855). Gluz O, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates RE, Kreipe HH, Hartmann A, Pelz E, Erber R, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Harbeck N, EC-Doc investigators (West German Study Group/AGO-B)

Genesis on diamonds II: contact with diamond enhances human sperm performance by 300. Ann Transl Med. 2016;4(20): 407 (Impact: liegt nicht vor). Sommer AP, Jaganathan S, Maduro MR, Hancke K, Janni W, Fecht HJ

Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial. Anticancer Res. 2016;36(9): 4771-6 (Impact(2016)=1.937). Hepp P, Andergassen U, Jäger B, Trapp E, Alunni-Fabbroni M, Friedl TW, Hecker N, Lorenz R, Fasching P, Schneeweiss A, Fehm T, Janni W, Rack B

Expression of Activin During and After Chemotherapy in Peripheral Blood of Patients with Primary Breast Cancer. Anticancer Res. 2016;36(5): 2153-9 (Impact(2016)=1.937). Jueckstock J, Burkhardt N, Kuhn C, Blankenstein T, Mahner S, Schindlbeck C, Janni W, Rack B, Mylonas I

Determination of Interleukin-4, -5, -6, -8 and -13 in Serum of Patients with Breast Cancer Before Treatment and its Correlation to Circulating Tumor Cells. Anticancer Res. 2016;36(6): 3123-30 (Impact(2016)=1.937). König A, Vilsmaier T, Rack B, Friese K, Janni W, Jeschke U, Andergassen U, Trapp E, Jückstock J, Jäger B, Alunni-Fabbroni M, Friedl T, Weissenbacher T, SUCCESS STUDY GROUP

Influence of Circulating Tumour Cells on Production of IL-1?, IL-1? and IL-12 in Sera of Patients with Primary Diagnosis of Breast Cancer Before Treatment. Anticancer Res. 2016;36(10): 5227-5236 (Impact(2016)=1.937). Vilsmaier T, Rack B, König A, Friese K, Janni W, Jeschke U, Weissenbacher T, SUCCESS Study Group

Comparison of seroma production in breast conserving surgery with or without intraoperative radiotherapy as tumour bed boost. Arch Gynecol Obstet. 2016;294(4): 861-6 (Impact(2016)=2.09). Ebner F, Schramm A, Bottke D, Friedl TW, Wiegel T, Fink V, Lato K, Bekes I, Janni W, de Gregorio N

Predictors for a successful external cephalic version: a single centre experience. Arch Gynecol Obstet. 2016;293(4): 749-55 (Impact(2016)=2.09). Ebner F, Friedl TW, Leinert E, Schramm A, Reister F, Lato K, Janni W, DeGregorio N

Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Arch Gynecol Obstet. 2016;293(2): 271-81 (Impact(2016)=2.09). Schramm A, Friedl TW, Schochter F, Scholz C, de Gregorio N, Huober J, Rack B, Trapp E, Alunni-Fabbroni M, Müller V, Schneeweiss A, Pantel K, Meier-Stiegen F, Hartkopf A, Taran FA, Wallwiener D, Janni W, Fehm T

Do T1a breast cancers profit from adjuvant systemic therapy? A multicenter retrospective cohort study of 325 T1a-patients. Arch Gynecol Obstet. 2016;294(2): 377-84 (Impact(2016)=2.09). Wolters R, Ebner F, Janni W, Novopashenny I, Wöckel A, Kreienberg R, Wischnewsky M, Schwentner L, Brenda study group

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. BMC Cancer. 2016;16: 522 (Impact(2016)=3.288). Aktas B, Kasimir-Bauer S, Müller V, Janni W, Fehm T, Wallwiener D, Pantel K, Tewes M, DETECT Study Group

Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer. BMC Cancer. 2016;16: 307 (Impact(2016)=3.288). Diessner J, Wischnewsky M, Stüber T, Stein R, Krockenberger M, Häusler S, Janni W, Kreienberg R, Blettner M, Schwentner L, Wöckel A, Bartmann C

Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial. BMC Cancer. 2016;16: 401 (Impact(2016)=3.288). Jueckstock J, Rack B, Friedl TW, Scholz C, Steidl J, Trapp E, Tesch H, Forstbauer H, Lorenz R, Rezai M, Häberle L, Alunni-Fabbroni M, Schneeweiss A, Beckmann MW, Lichtenegger W, Fasching PA, Pantel K, Janni W, SUCCESS Study Group

The impact of breast cancer biological subtyping on tumor size assessment by ultrasound and mammography - a retrospective multicenter cohort study of 6543 primary breast cancer patients. BMC Cancer. 2016;16: 459 (Impact(2016)=3.288). Stein RG, Wollschläger D, Kreienberg R, Janni W, Wischnewsky M, Diessner J, Stüber T, Bartmann C, Krockenberger M, Wischhusen J, Wöckel A, Blettner M, Schwentner L, BRENDA Study Group

Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment. BMC Cancer. 2016;16: 547 (Impact(2016)=3.288). Vilsmaier T, Rack B, Janni W, Jeschke U, Weissenbacher T, SUCCESS Study Group

Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study. Br J Cancer. 2016;114(8): 863-71 (Impact(2016)=6.176). Janni W, Harbeck N, Rack B, Augustin D, Jueckstock J, Wischnik A, Annecke K, Scholz C, Huober J, Zwingers T, Friedl TW, Kiechle M

Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial. Breast. 2016;27: 69-77 (Impact(2016)=2.801). Schwentner L, Harbeck N, Singer S, Eichler M, Rack B, Forstbauer H, Wischnik A, Scholz C, Huober J, Friedl TW, Weissenbacher T, Härtl K, Kiechle M, Janni W, Fink V

Radiotherapy effects on early breast cancer survival in observational and randomized studies: a systematic analysis of advantages, disadvantages and differences between the two study types. Breast Cancer. 2016;23(3): 415-24 (Impact(2016)=1.572). König J, van Ewijk R, Kuhr K, Schmidberger H, Wöckel A, Kreienberg R, Blettner M

Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Res. 2016;18(1): 112 (Impact(2016)=6.345). Rebbeck TR, ..., Wang-Gohrke S, ..., Ramus SJ

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res. 2016;18(1): 64 (Impact(2016)=6.345). Zeng C, ..., Wang-Gohrke S, ..., Zheng W

Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. Breast Cancer Res Treat. 2016;158(1): 59-65 (Impact(2016)=3.626). Hein A, Gass P, Walter CB, Taran FA, Hartkopf A, Overkamp F, Kolberg HC, Hadji P, Tesch H, Ettl J, Wuerstlein R, Lounsbury D, Lux MP, Lüftner D, Wallwiener M, Müller V, Belleville E, Janni W, Fehm TN, Wallwiener D, Ganslandt T, Ruebner M, Beckmann MW, Schneeweiss A, Fasching PA, Brucker SY

Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. Breast Care (Basel). 2016;11(5): 315-322 (Impact(2016)=1.553). Gaß P, Fasching PA, Fehm T, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesselt T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Hadji P, Brucker SY, Beckmann MW, Wallwiener D, Kümmel S, Löhberg CR

Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes Control. 2016;27(5): 679-93 (Impact(2016)=2.51). Zhao Z, ..., Wang-Gohrke S, ..., Zheng W

Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. Cancer Epidemiol Biomarkers Prev. 2016;25(5): 780-90 (Impact(2016)=4.142). Usset JL, Raghavan R, Tyrer JP, McGuire V, Sieh W, Webb P, Chang-Claude J, Rudolph A, Anton-Culver H, Berchuck A, Brinton L, Cunningham JM, DeFazio A, Doherty JA, Edwards RP, Gayther SA, Gentry-Maharaj A, Goodman MT, Høgdall E, Jensen A, Johnatty SE, Kiemeney LA, Kjaer SK, Larson MC, Lurie G, Massuger L, Menon U, Modugno F, Moysich KB, Ness RB, Pike MC, Ramus SJ, Rossing MA, Rothstein J, Song H, Thompson PJ, van den Berg DJ, Vierkant RA, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wilkens LR, Wu AH, Yang H, Pearce CL, Schildkraut JM, Pharoah P, Goode EL, Fridley BL, Ovarian Cancer Association Consortium and the Australian Cancer Study

Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer? Cancer Treat Rev. 2016;48: 8-19 (Impact(2016)=8.589). Macerelli M, Ganzinelli M, Gouedard C, Broggini M, Garassino MC, Linardou H, Damia G, Wiesmüller L

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. Clin Cancer Res. 2016;22(15): 3755-63 (Impact(2016)=9.619). Baselga J, Lewis Phillips GD, Verma S, Ro J, Huober J, Guardino AE, Samant MK, Olsen S, de Haas SL, Pegram MD

Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Clin Cancer Res. 2016;22(10): 2583-93 (Impact(2016)=9.619). Janni WJ, Rack B, Terstappen LW, Pierga JY, Taran FA, Fehm T, Hall C, de Groot MR, Bidard FC, Friedl TW, Fasching PA, Brucker SY, Pantel K, Lucci A

Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. Clin Cancer Res. 2016;22(11): 2675-83 (Impact(2016)=9.619). Loibl S, Darb-Esfahani S, Huober J, Klimowicz A, Furlanetto J, Lederer B, Hartmann A, Eidtmann H, Pfitzner B, Fasching PA, Tiemann K, Jackisch C, Mehta K, von Minckwitz G, Untch M, Denkert C

The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer. Curr Med Res Opin. 2016;32(7): 1217-24 (Impact(2016)=2.757). Wuerstlein R, Sotlar K, Gluz O, Otremba B, von Schumann R, Witzel I, Schindlbeck C, Janni W, Schem C, Bauerfeind I, Hasmueller S, Tesch H, Paulenz A, Ghali N, Orujov E, Kates RE, Cowens W, Hornberger J, Pelz E, Harbeck N

Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial. Eur J Cancer. 2016;63: 97-104 (Impact(2016)=6.029). Ignatiadis M, Rack B, Rothé F, Riethdorf S, Decraene C, Bonnefoi H, Dittrich C, Messina C, Beauvois M, Trapp E, Goulioti T, Tryfonidis K, Pantel K, Repollet M, Janni W, Piccart M, Sotiriou C, Litiere S, Pierga JY

Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer. 2016;53: 65-74 (Impact(2016)=6.029). Marmé F, Lederer B, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kümmel S, Loibl S, Paepke S, Untch M, von Minckwitz G, Schneeweiss A

Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study. Eur J Cancer. 2016;69: 180-188 (Impact(2016)=6.029). Woelber L, Griebel LF, Eulenburg C, Sehouli J, Jueckstock J, Hilpert F, de Gregorio N, Hasenburg A, Ignatov A, Hillemanns P, Fuerst S, Strauss HG, Baumann KH, Thiel FC, Mustea A, Meier W, Harter P, Wimberger P, Hanker LC, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, Neuser P, Mahner S

Corrigendum to "Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group" [Eur J Cancer 49 (2013) 1905-1914]. Eur J Cancer. 2016;65: 192-193 (Impact(2016)=6.029). du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss S, Hauptmann S

Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). Eur J Cancer. 2016;64: 12-21 (Impact(2016)=6.029). von Minckwitz G, Rezai M, Tesch H, Huober J, Gerber B, Zahm DM, Hilfrich J, Costa SD, Dubsky P, Blohmer JU, Denkert C, Hanusch C, Jackisch C, Kümmel S, Fasching PA, Schneeweiss A, Paepke S, Untch M, Burchardi N, Mehta K, Loibl S, German Breast Group and Austrian Breast and Colon Cancer Study Group Investigators

In vitro model for DNA double-strand break repair analysis in breast cancer reveals cell type-specific associations with age and prognosis. FASEB J. 2016;30(11): 3786-3799 (Impact(2016)=5.498). Deniz M, Kaufmann J, Stahl A, Gundelach T, Janni W, Hoffmann I, Keimling M, Hampp S, Ihle M, Wiesmüller L

Evidence of a genetic link between endometriosis and ovarian cancer. Fertil Steril. 2016;105(1): 35-43.e10 (Impact(2016)=4.373). Lee AW, ..., Wang-Gohrke S, ..., Shvetsov YB

Psychosocial Risk Factors for Child Welfare among Postpartum Mothers with a History of Childhood Maltreatment and Neglect.
Geburtshilfe Frauenheilkd. 2016;76(3): 261-267 (Impact(2016)=1.07). Koenig AM, Schury K, Reister F, Köhler-Dauner F, Schauer M, Ruf-Leuschner M, Gündel H, Ziegenhain U, Fegert JM, Kolassa IT

Oncology Move yourself and Your Immune System - what causes physical Activity? Geburtshilfe Frauenheilkd. 2016;76(1): 23-25 (Impact(2016)=1.07) Otto S, Ebner F

Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial. Geburtshilfe Frauenheilkd. 2016;76(5): 542-550 (Impact(2016)=1.07) Schröder L, Rack B, Sommer H, Koch JG, Weissenbacher T, Janni W, Schneeweiss A, Rezai M, Lorenz R, Jäger B, Schramm A, Häberle L, Fasching PA, Friedl TW, Beckmann MW, Scholz C

Oncology Surgical Treatment of the Vulvar Carcinoma - How much Radicalism is required? Geburtshilfe Frauenheilkd. 2016;76(7): 764-766 (Impact(2016)=1.07). de Gregorio N, Schramm A, Ebner F, Janni W

Documentation Time and Effort and Associated Resources for Patients with Primary Breast Cancer from Diagnosis to End of Follow-Up - Results of a Multicentre Validation. Gesundheitswesen. 2016;78(7): 438-45 (Impact(2016)=0.538). Beckmann M, Sell C, Aydogdu M, Brucker SY, Fehm T, Janni W, Kreienberg R, Kümmel S, Neumann M, Scharl A, Schleicher B, Wallwiener D, Wöckel A, Fasching PA, Lux MP

Breastfeeding Rates and Duration in Germany - A Systematic Review. Gesundheitswesen. 2016;78(11): 695-707 (Impact(2016)=0.538). Weissenborn A, Abou-Dakn M, Bergmann R, Both D, Gresens R, Hahn B, Hecker A, Koletzko B, Krawinkel M, Kroll D, Rouw E, Scheele M, Schwegler U, Sievers E, Sporleder E, Springer S, Vetter K, Wöckel A, Kersting M

Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8). Gynecol Oncol. 2016;140(3): 450-6 (Impact(2016)=4.959). Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner ML, Hanker L, Thiel F, Hilpert F

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol. 2016;141(2): 386-401 (Impact(2016)=4.959). Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2 , Hollestelle A, ..., Wang-Gohrke S, ..., Goode EL

Drug therapy of otorhinolaryngological diseases in pregnancy : An update. HNO. 2016;64(11): 843-854 (Impact(2016)=0.723). Riepl R, Friebe-Hoffmann U

Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet. 2016;135(7): 741-56 (Impact(2016)=4.637). Cuellar-Partida G, ..., Wang-Gohrke S, ..., Webb PM, Chenevix-Trench G, Risch HA, MacGregor S

MCM3AP and POMP Mutations Cause a DNA-Repair and DNA-Damage-Signaling Defect in an Immunodeficient Child. Hum Mutat. 2016;37(3): 257-68 (Impact(2016)=4.601). Gatz SA, Salles D, Jacobsen EM, Dörk T, Rausch T, Aydin S, Surowy H, Volcic M, Vogel W, Debatin KM, Stütz AM, Schwarz K, Pannicke U, Hess T, Korbel JO, Schulz AS, Schumacher J, Wiesmüller L

Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. Int J Epidemiol. 2016;45(5): 1619-1630 (Impact(2016)=7.738). Ong JS, ..., Wang-Gohrke S, ..., MacGregor S

Disseminated and circulating tumor cells in bone marrow and blood of breast cancer patients: properties, enrichment, and potential targets. J Cancer Res Clin Oncol. 2016;142(9): 1883-95 (Impact(2016)=3.503). Schindlbeck C, Andergassen U, Jueckstock J, Rack B, Janni W, Jeschke U

Surgical treatment of melanoma in pregnancy: a practical guideline. J Dtsch Dermatol Ges. 2016;14(6): 585-93 (Impact(2016)=2.865). Crisan D, Treiber N, Kull T, Widschwendter P, Adolph O, Schneider LA

Chirurgische Behandlung von Melanomen in der Schwangerschaft: eine praktische Anleitung. J Dtsch Dermatol Ges. 2016;14(6): 585-94 (Impact(2016)=2.865). Crisan D, Treiber N, Kull T, Widschwendter P, Adolph O, Schneider LA

Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. J Med Genet. 2016;53(7): 465-71 (Impact(2016)=5.451). Kast K, Rhiem K, Wappenschmidt B, Hahnen E, Hauke J, Bluemcke B, Zarghooni V, Herold N, Ditsch N, Kiechle M, Braun M, Fischer C, Dikow N, Schott S, Rahner N, Niederacher D, Fehm T, Gehrig A, Mueller-Reible C, Arnold N, Maass N, Borck G, de Gregorio N, Scholz C, Auber B, Varon-Manteeva R, Speiser D, Horvath J, Lichey N, Wimberger P, Stark S, Faust U, Weber BH, Emons G, Zachariae S, Meindl A, Schmutzler RK, Engel C, German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC)

PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet. 2016;53(12): 800-811 (Impact(2016)=5.451). Southey MC, ..., Wang-Gohrke S, ..., Milne RL

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol. 2016; (Impact(2016)=16.559). Fumagalli D, Venet D, Ignatiadis M, Azim HA, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Peña L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C

Risk Factors Associated with Intraventricular Hemorrhage in Preterm Infants with <=28 Weeks Gestational Age. Klin Padiatr. 2016;228(5): 245-50 (Impact(2016)=0.731). Waitz M, Nusser S, Schmid MB, Dreyhaupt J, Reister F, Hummler H

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2016;17(1): 78-89 (Impact(2016)=33.9). du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P, AGO Study Group led Gynecologic Cancer Intergroup (GCIG)/European Network of Gynaecologic Oncology Trials Groups (ENGOT) Intergroup Consortium

Fertility preservation in female cancer patients. MMW Fortschr Med. 2016;158(19): 47-50 (Impact: liegt nicht vor). Hancke K, Döhmen G

Metformin for the treatment of polycystic ovary syndrome. Med Monatsschr Pharm. 2016;39(2): 75-8 (Impact: liegt nicht vor). Gundelach T, Rodewald M, Bekes I, Janni W, Hancke K

Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer? Mol Cancer. 2016;15: 13 (Impact(2016)=6.204). Bekes I, Friedl TW, Köhler T, Möbus V, Janni W, Wöckel A, Wulff C

Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer. Mol Oncol. 2016;10(8): 1330-43 (Impact(2016)=5.314). Gasch C, Oldopp T, Mauermann O, Gorges TM, Andreas A, Coith C, Müller V, Fehm T, Janni W, Pantel K, Riethdorf S

Microbiological screening in preterm infants. Results and consequences for hygiene management. Monatsschr Kinderheilkd. 2016;164(9): 805-812 (Impact(2016)=0.31). Lindner W, Essig A, Hummler HD, Reister F, von Baum H

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18): 1738-1748 (Impact(2016)=72.406). Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J

Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nat Commun. 2016;7: 11375 (Impact(2016)=12.124). Couch FJ, Kuchenbaecker KB, ..., Wang-Gohrke S, ..., García-Closas M, Easton DF, Antoniou AC

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun. 2016;7: 12675 (Impact(2016)=12.124). Lawrenson K, ..., Wang-Gohrke S, ..., Webb P

Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients. Oncogene. 2016;35(29): 3796-806 (Impact(2016)=7.519). Obermeier K, Sachsenweger J, Friedl TW, Pospiech H, Winqvist R, Wiesmüller L

Targeted Therapy of Breast Cancer. Oncol Res Treat. 2016;39(3): 100-1 (Impact(2016)=1.667). Janni W

Liquid Biopsy in Metastasized Breast Cancer as Basis for Treatment Decisions. Oncol Res Treat. 2016;39(3): 112-6 (Impact(2016)=1.667). Krawczyk N, Fehm T, Banys-Paluchowski M, Janni W, Schramm A

Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients. Oncology. 2016;90(4): 232-8 (Impact(2016)=2.262). Rack B, Zombirt E, Trapp E, Jückstock J, Andergassen U, Neugebauer J, Kost B, Weissenbacher T, Jeschke U, Schindlbeck C, Janni W, Alunni-Fabbroni M

The DETECT Study Concept - Individualized Therapy of Metastatic Breast Cancer Based on Circulating Tumor Cells. Oncology Research and Treatment. 2016;39(4): 227-229 (Impact(2016)=1.667). Janni W, Polasik A

Why this Trial Is Important to Us Expert Commentary. Oncology Research and Treatment. 2016;39(4): 230-230 (Impact(2016)=1.667). Polasik A, Fehm T

Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget. 2016;7(43): 69097-69110 (Impact(2016)=5.168). Hampras SS, ..., Wang-Gohrke S, ..., Australian Ovarian Canc Study Grp

Sentinel lymph nodes in gynecological malignancies. Onkologe. 2016;22(12): 999-1010 (Impact(2016)=0.087). Widschwendter P, DeGregorio N, Beer A, Ebner F, Kull T, Janni W, Scholz C

Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study. PLoS ONE. 2016;11(12): e0168730 (Impact(2016)=2.806). Diessner J, Wischnewsky M, Blettner M, Häusler S, Janni W, Kreienberg R, Stein R, Stüber T, Schwentner L, Bartmann C, Wöckel A

Delivery Mode, Duration of Labor, and Cord Blood Adiponectin, Leptin, and C-Reactive Protein: Results of the Population-Based Ulm Birth Cohort Studies. PLoS ONE. 2016;11(2): e0149918 (Impact(2016)=2.806, Typ=Article; Journal Article; Research Support, Non-U.S. Gov't). Logan CA, Thiel L, Bornemann R, Koenig W, Reister F, Brenner H, Rothenbacher D, Genuneit J

The Association of Hair Cortisol with Self-Reported Chronic Psychosocial Stress and Symptoms of Anxiety and Depression in Women Shortly after Delivery. Paediatr Perinat Epidemiol. 2016;30(2): 97-104 (Impact(2016)=2.724). Braig S, Grabher F, Ntomchukwu C, Reister F, Stalder T, Kirschbaum C, Rothenbacher D, Genuneit J

Changing Societal and Lifestyle Factors and Breastfeeding Patterns Over Time. Pediatrics. 2016;137(5) (Impact(2016)=5.705). Logan C, Zittel T, Striebel S, Reister F, Brenner H, Rothenbacher D, Genuneit J

DNA damage tolerance pathway involving DNA polymerase ? and the tumor suppressor p53 regulates DNA replication fork progression. Proc Natl Acad Sci U S A. 2016;113(30): E4311-9 (Impact(2016)=9.661). Hampp S, Kiessling T, Buechle K, Mansilla SF, Thomale J, Rall M, Ahn J, Pospiech H, Gottifredi V, Wiesmüller L

The course of psychiatric co-morbidity in patients with breast cancer - results from the prospective multi-centre BRENDA II study. Psychooncology. 2016;25(5): 590-6 (Impact(2016)=3.095). Singer S, Schwentner L, van Ewijk R, Blettner M, Wöckel A, Kühn T, Felberbaum R, Flock F, Janni W, BRENDA Study Group.

Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy-results from the prospective multi-center study BRENDA II. Support Care Cancer. 2016;24(6): 2759-66 (Impact(2016)=2.698). Schwentner L, Van Ewijk R, Kühn T, Flock F, Felberbaum R, Blettner M, Kreienberg R, Janni W, Wöckel A, Singer S

CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients. Tumour Biol. 2016;37(10): 13769-13775 (Impact(2016)=3.65). Rack B, Jückstock J, Trapp E, Weissenbacher T, Alunni-Fabbroni M, Schramm A, Widschwendter P, Lato K, Zwingers T, Lorenz R, Tesch H, Schneeweiss A, Fasching P, Mahner S, Beckmann MW, Lichtenegger W, Janni W, SUCCESS Study Group

The Wolf-Hirschhorn Syndrome. Z Geburtshilfe Neonatol. 2016;220(5): 195-199 (Impact(2016)=0.476). Friebe-Hoffmann U, Reister F, Gaspar H, Hummler H, Lindner W, Lato K

Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8): 1533-46 (Impact(2015)=9.269, Impact(2016)=11.855). Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ, Panel Members , André F, Baselga J, Bergh J, Bonnefoi H, Burstein H, Cardoso F, Castiglione-Gertsch M, Coates AS, Colleoni M, Curigliano G, Davidson NE, Di Leo A, Ejlertsen B, Forbes JF, Galimberti V, Gelber RD, Gnant M, Goldhirsch A, Goodwin P, Harbeck N, Hayes DF, Huober J, Hudis CA, Ingle JN, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Kent Osborne C, Partridge AH, de la Peña L, Piccart-Gebhart MJ, Pritchard KI, Rutgers EJ, Sedlmayer F, Semiglazov V, Shao ZM, Smith I, Thürlimann B, Toi M, Tutt A, Viale G, von Minckwitz G, Watanabe T, Whelan T, Winer EP, Xu B

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy+. Ann Oncol. 2015;26(1): 95-100 (Impact(2015)=9.269, Impact(2016)=11.855). Lindner JL, Loibl S, Denkert C, Ataseven B, Fasching PA, Pfitzner BM, Gerber B, Gade S, Darb-Esfahani S, Sinn BV, Huober J, Engels K, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Müller V, Rack B, Schem C, von Minckwitz G

Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study. Arch Gynecol Obstet. 2015;292(3): 655-64 (Impact(2015)=1.68, Impact(2016)=2.09). Diessner J, Van Ewijk R, Weiss CR, Janni W, Wischnewsky MB, Kreienberg R, Hancke K, Blettner M, Wöckel A, Schwentner L

Is open surgery the solution to avoid morcellation of uterine sarcomas? A systematic literature review on the effect of tumor morcellation and surgical techniques. Arch Gynecol Obstet. 2015;292(3): 499-506 (Impact(2015)=1.68, Impact(2016)=2.09). Ebner F, Friedl TW, Scholz C, Schochter F, Janni W, Vorwerk E, deGregorio N

Treatment cost evaluation of extrauterine gravidity: a literature review of medical and surgical treatment costs. Arch Gynecol Obstet. 2015;291(3): 493-8 (Impact(2015)=1.68, Impact(2016)=2.09). Ebner F, Varga D, Sorg F, Vorwerk E, Schochter F, Janni W, Wöckel A, DeGregorio N

Response to: Importance of work-life balance among German medical students who wish to become gynecologists. Arch Gynecol Obstet. 2015;291(2): 241 (Impact(2015)=1.68, Impact(2016)=2.09). Hancke K, Igl W, Toth B, Bühren A, Ditsch N, Kreienberg R

Adjuvant therapeutic decisions in elderly breast cancer patients: the role of chemotherapy in a retrospective analysis. Arch Gynecol Obstet. 2015;292(5): 1101-7 (Impact(2015)=1.68, Impact(2016)=2.09). Jueckstock J, Kasch F, Jaeger B, Schramm A, Janni W, Scholz C

The ratio of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16?-hydroxyestrone (16-OHE1) may predict breast cancer risk in postmenopausal but not in premenopausal women: two case-control studies. Arch Gynecol Obstet. 2015;291(5): 1141-6 (Impact(2015)=1.68, Impact(2016)=2.09). Ruan X, Seeger H, Wallwiener D, Huober J, Mueck AO

Is guideline-adherent adjuvant treatment an equal alternative for patients aged >65 who cannot participate in adjuvant clinical breast cancer trials? A retrospective multi-center cohort study of 4,142 patients.
Arch Gynecol Obstet. 2015;291(3): 631-40 (Impact(2015)=1.68, Impact(2016)=2.09). Van Ewijk R, Wöckel A, Gundelach T, Hancke K, Janni W, Singer S, Kreienberg R, Blettner M, Schwentner L

Rapid correction of severe hyponatremia after hysteroscopic surgery - a case report. BMC Anesthesiol. 2015;15: 85 (Impact(2015)=1.32, Impact(2016)=1.525). Hepp P, Jüttner T, Beyer I, Fehm T, Janni W, Monaca E

Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study. Br J Cancer. 2015;112(4): 660-6 (Impact(2015)=5.569, Impact(2016)=6.176). Trillsch F, Mahner S, Vettorazzi E, Woelber L, Reuss A, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Fotopoulou C, Schmalfeldt B, Burges A, Ewald-Riegler N, de Gregorio N, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Kommoss S, Kommoss F, Hauptmann S, du Bois A

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients. Br J Clin Pharmacol. 2015;80(5): 1139-48 (Impact(2015)=3.83, Impact(2016)=3.493). Bachmann HS, Meier W, du Bois A, Kimmig R, Kuhlmann JD, Siffert W, Sehouli J, Wollschlaeger K, Huober J, Hillemanns P, Burges A, Schmalfeldt B, Aminossadati B, Wimberger P

Tumor biology in older breast cancer patients--what is the impact on survival stratified for guideline adherence? A retrospective multi-centre cohort study of 5378 patients. Breast. 2015;24(3): 256-62 (Impact(2015)=2.74, Impact(2016)=2.801). Ebner F, van Ewijk R, Wöckel A, Hancke K, Schwentner L, Fink V, Kreienberg R, Janni W, Blettner M

Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer. Breast. 2015;24(6): 769-73 (Impact(2015)=2.74, Impact(2016)=2.801). Janni W, Sarosiek T, Karaszewska B, Pikiel J, Staroslawska E, Potemski P, Salat C, Brain E, Caglevic C, Briggs K, Mahood K, DeSilvio M, Marini L, Papadimitriou C

Quality of care in breast cancer centers: Results of benchmarking by the German Cancer Society and German Society for Breast Diseases. Breast. 2015;24(2): 118-23 (Impact(2015)=2.74, Impact(2016)=2.801). Kowalski C, Ferencz J, Brucker SY, Kreienberg R, Wesselmann S

An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res. 2015;17: 61 (Impact(2015)=5.211, Impact(2016)=6.345). Blein S, ..., Wang-Gohrke S, ..., Cox DG

The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Res. 2015;17: 129 (Impact(2015)=5.211, Impact(2016)=6.345). Widschwendter P, Friedl TW, Schwentner L, DeGregorio N, Jaeger B, Schramm A, Bekes I, Deniz M, Lato K, Weissenbacher T, Kost B, Andergassen U, Jueckstock J, Neugebauer J, Trapp E, Fasching PA, Beckmann MW, Schneeweiss A, Schrader I, Rack B, Janni W, Scholz C

Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. Breast Cancer Res Treat. 2015;150(2): 279-88 (Impact(2015)=4.085, Impact(2016)=3.626). Erber R, Gluz O, Brünner N, Kreipe HH, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Moustafa Z, Liedtke C, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Hartmann A

Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat. 2015;150(1): 127-39 (Impact(2015)=4.085, Impact(2016)=3.626). Fontanella C, Lederer B, Gade S, Vanoppen M, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Schneeweiss A, Paepke S, Jackisch C, Mehta K, Nekljudova V, Untch M, Neven P, von Minckwitz G, Loibl S

Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Breast Cancer Res Treat. 2015;152(2): 377-87 (Impact(2015)=4.085, Impact(2016)=3.626). Loibl S, Jackisch C, Lederer B, Untch M, Paepke S, Kümmel S, Schneeweiss A, Huober J, Hilfrich J, Hanusch C, Gerber B, Eidtmann H, Denkert C, Costa SD, Blohmer JU, Nekljudova V, Mehta K, von Minckwitz G

Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer. Breast Cancer Res Treat. 2015;149(1): 141-9 (Impact(2015)=4.085, Impact(2016)=3.626). Lück HJ, Lübbe K, Reinisch M, Maass N, Feisel-Schwickardi G, Tomé O, Janni W, Aydogdu M, Neunhöffer T, Ober A, Aktas B, Park-Simon TW, Schumacher C, Höffkes HG, Illmer T, Wagner H, Mehta K, von Minckwitz G, Nekljudova V, Loibl S

Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer. Breast Cancer Res Treat. 2015;151(3): 569-76 (Impact(2015)=4.085, Impact(2016)=3.626). Scholz C, Andergassen U, Hepp P, Schindlbeck C, Friedl TW, Harbeck N, Kiechle M, Sommer H, Hauner H, Friese K, Rack B, Janni W

Guidelines are advantageous, though not essential for improved survival among breast cancer patients. Breast Cancer Res Treat. 2015;152(2): 357-66 (Impact(2015)=4.085, Impact(2016)=3.626). Wolters R, Wischhusen J, Stüber T, Weiss CR, Krockberger M, Bartmann C, Blettner M, Janni W, Kreienberg R, Schwentner L, Novopashenny I, Wischnewsky M, Wöckel A, Diessner J

Bispohosphonates in the Treatment of Breast Cancer. Breast Care (Basel). 2015;10(3): 220-221 (Impact(2015)=1.645, Impact(2016)=1.553). Fehm T, Janni W, Ruckhaberle E, Schutz F, Solomayer EF

News from ASCO 2015-What Was Relevant for Breast Cancer Experts? Breast Care (Basel). 2015;10(4): 285-288 (Impact(2015)=1.645, Impact(2016)=1.553). Huober J, Decker T, Liedtke C, Marme F, Marschner N, Muller V

14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care (Basel). 2015;10(3): 211-9 (Impact(2015)=1.645, Impact(2016)=1.553). Jackisch C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe HH, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Thomssen C, Loibl S, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Fasching PA, Fehm T, Janni W, Lück HJ, Maass N, Scharl A, Untch M

Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review. Breast Care (Basel). 2015;10(3): 173-8 (Impact(2015)=1.645, Impact(2016)=1.553). Schramm A, De Gregorio N, Widschwendter P, Fink V, Huober J

Breast Cancer Patients' Fear of Treatment: Results from the Multicenter Longitudinal Study BRENDA II. Breast Care (Basel). 2015;10(2): 95-100 (Impact(2015)=1.645, Impact(2016)=1.553). Singer S, Blettner M, Kreienberg R, Janni W, Wöckel A, Kühn T, Felberbaum R, Flock F, Schwentner L, BRENDA II study group

Reply to Schrodi et al. 2015. Breast J. 2015;21(6): 699-701 (Impact(2015)=1.92, Impact(2016)=2.297). Kowalski C, Wesselmann S, Kuhr K, Wallwiener D, Kreienberg R

A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
Cancer. 2015;121(20): 3639-48 (Impact(2015)=5.649, Impact(2016)=5.997). von Minckwitz G, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marmé F, Potenberg J, Stickeler E, Simon E, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S, German Breast Group Investigators

Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2015;24(10): 1574-84 (Impact(2015)=3.622, Impact(2016)=4.142). Kar SP, ..., Wang-Gohrke S, ..., Pharoah PD

Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiol Biomarkers Prev. 2015;24(1): 308-16 (Impact(2015)=3.622, Impact(2016)=4.142). Peterlongo P, ..., Wang-Gohrke S, ..., Antoniou AC, Friedman E

Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration of Regulatory T Cells and Blocks Cancer Progression. Cancer Res. 2015;75(21): 4483-93 (Impact(2015)=8.556, Impact(2016)=9.122). Anz D, Rapp M, Eiber S, Koelzer VH, Thaler R, Haubner S, Knott M, Nagel S, Golic M, Wiedemann GM, Bauernfeind F, Wurzenberger C, Hornung V, Scholz C, Mayr D, Rothenfusser S, Endres S, Bourquin C

A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer. Cancer Treat Rev. 2015;41(2): 94-104 (Impact(2015)=7.983, Impact(2016)=8.589). Jerusalem G, Bachelot T, Barrios C, Neven P, Di Leo A, Janni W, de Boer R

Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. Carcinogenesis. 2015;36(11): 1341-53 (Impact(2015)=4.874, Impact(2016)=5.105). Lawrenson K, ..., Wang-Gohrke S, ..., Schildkraut JM

Aggressive Intrinsic Subtypes in Breast Cancer: A Predictor of Guideline Adherence in Older Patients With Breast Cancer? Clin Breast Cancer. 2015;15(4): e189-95 (Impact(2015)=3.082, Impact(2016)=2.816). Ebner F, Hancke K, Blettner M, Schwentner L, Wöckel A, Kreienberg R, Janni W, van Ewijk R

Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70). Clin Cancer Res. 2015;21(13): 2924-31 (Impact(2015)=8.738, Impact(2016)=9.619). Hanusch C, Schneeweiss A, Loibl S, Untch M, Paepke S, Kümmel S, Jackisch C, Huober J, Hilfrich J, Gerber B, Eidtmann H, Denkert C, Costa S, Blohmer JU, Engels K, Burchardi N, von Minckwitz G

Standardized Ki67 Diagnostics Using Automated Scoring-Clinical Validation in the GeparTrio Breast Cancer Study. Clin Cancer Res. 2015;21(16): 3651-7 (Impact(2015)=8.738, Impact(2016)=9.619). Klauschen F, Wienert S, Schmitt W, Loibl S, Gerber B, Blohmer JU, Huober J, Ruediger T, Erbstoesser E, Mehta K, Lederer B, Dietel M, Denkert C, von Minckwitz G

Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers. Clin Cancer Res. 2015;21(8): 1962-72 (Impact(2015)=8.738, Impact(2016)=9.619). Lombardi AJ, Hoskins EE, Foglesong GD, Wikenheiser-Brokamp KA, Wiesmüller L, Hanenberg H, Andreassen PR, Jacobs AJ, Olson SB, Keeble WW, Hays LE, Wells SI

Leukemogenic rearrangements at the mixed lineage leukemia gene (MLL)-multiple rather than a single mechanism. Front Cell Dev Biol. 2015;3: 41 (Impact: liegt nicht vor). Gole B, Wiesmüller L

Impact of Charged Particle Exposure on Homologous DNA Double-Strand Break Repair in Human Blood-Derived Cells. Front Oncol. 2015;5: 250 (Impact: liegt nicht vor). Rall M, Kraft D, Volcic M, Cucu A, Nasonova E, Taucher-Scholz G, Bönig H, Wiesmüller L, Fournier C

Does patient education work in breast cancer? Final results from the global CARIATIDE study. Future Oncol. 2015;11(2): 205-17 (Impact(2015)=2.129, Impact(2016)=2.131). Markopoulos C, Neven P, Tanner M, Marty M, Kreienberg R, Atkins L, Franquet A, Gnant M, Neciosup S, Tesarova P, Barni S, Deschamp V

Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. Geburtshilfe Frauenheilkd. 2015;75(1): 41-50 (Impact(2015)=0.931, Impact(2016)=1.07). Fasching PA, Brucker SY, Fehm TN, Overkamp F, Janni W, Wallwiener M, Hadji P, Belleville E, Häberle L, Taran FA, Lüftner D, Lux MP, Ettl J, Müller V, Tesch H, Wallwiener D, Schneeweiss A

Breast Cancer Update 2014 - Focus on the Patient and the Tumour. Geburtshilfe Frauenheilkd. 2015;75(2): 170-182 (Impact(2015)=0.931, Impact(2016)=1.07). Maass N, Schütz F, Fasching PA, Fehm T, Janni W, Kümmel S, Kolberg HC, Lüftner D, Wallwiener M, Lux MP

Hormone Therapy and its Effect on the Prognosis in Breast Cancer Patients. Geburtshilfe Frauenheilkd. 2015;75(6): 588-596 (Impact(2015)=0.931, Impact(2016)=1.07). Rauh C, Schuetz F, Rack B, Stickeler E, Klar M, Orlowska-Volk M, Windfuhr-Blum M, Heil J, Rom J, Sohn C, Andergassen U, Jueckstock J, Fehm T, Loehberg CR, Hein A, Schulz-Wendtland R, Hartmann A, Beckmann MW, Janni W, Fasching PA, Häberle L

Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy? Geburtshilfe Frauenheilkd. 2015;75(6): 574-583 (Impact(2015)=0.931, Impact(2016)=1.07). Schneeweiss A, Ruckhäberle E, Huober J

Finished? - The Checklist before Submission and Peer Review Process. Geburtshilfe Frauenheilkd. 2015;75(2): 126-128 (Impact(2015)=0.931, Impact(2016)=1.07). Schwentner L, Janni W

Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015).
Geburtshilfe Frauenheilkd. 2015;75(6): 556-565 (Impact(2015)=0.931, Impact(2016)=1.07). Untch M, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe HH, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Thomssen C, Jackisch C, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Fasching PA, Fehm T, Janni W, Lück HJ, Maass N, Scharl A, Loibl S

Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genet Epidemiol. 2015;39(8): 689-97 (Impact(2015)=2.553, Impact(2016)=1.884). Amankwah EK, ..., Wang-Gohrke S, ..., Phelan CM

Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecol Oncol. 2015;136(3): 542-8 (Impact(2015)=4.198, Impact(2016)=4.959). Lee AW, ..., Wang-Gohrke S, ..., Pearce CL

Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Hum Mol Genet. 2015;24(13): 3595-607 (Impact(2015)=5.985, Impact(2016)=5.34). Coetzee SG, ..., Wang-Gohrke S, ..., Ziogas A

Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Hum Mol Genet. 2015;24(20): 5955-64 (Impact(2015)=5.985, Impact(2016)=5.34). Lu Y, ..., Wang-Gohrke S, ..., Zondervan KT

Evaluation of Sentinel Lymph Node Dose Distribution in 3D Conformal Radiotherapy Techniques in 67 pN0 Breast Cancer Patients. Int J Breast Cancer. 2015;2015: 539842 (Impact: liegt nicht vor). Witucki G, Degregorio N, Rempen A, Schwentner L, Bottke D, Janni W, Ebner F

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. Int J Cancer. 2015;137(12): 2981-8 (Impact(2015)=5.531, Impact(2016)=6.513). Hein A, Lambrechts D, von Minckwitz G, Häberle L, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Dan Costa S, Blohmer JU, Schwedler K, Kittel K, Fehm T, Kunz G, Beckmann MW, Ekici AB, Hanusch C, Huober J, Liedtke C, Mau C, Moisse M, Müller V, Nekljudova V, Peuteman G, Rack B, Rübner M, Van Brussel T, Wang L, Weinshilboum RM, Loibl S, Fasching PA

The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study. Int J Gynecol Cancer. 2015;25(7): 1248-52 (Impact(2015)=2.116, Impact(2016)=2.369). Fotopoulou C, Sehouli J, Ewald-Riegler N, de Gregorio N, Reuss A, Richter R, Mahner S, Kommoss F, Schmalfeldt B, Fehm T, Hanker L, Wimberger P, Canzler U, Pfisterer J, Kommoss S, Hauptmann S, du Bois A, ROBOT investigators

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33(4): 304-11 (Impact(2015)=20.982, Impact(2016)=24.008). Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, Slettedahl S, Hallberg E, Guidugli L, Davila JI, Beckmann MW, Janni W, Rack B, Ekici AB, Slamon DJ, Konstantopoulou I, Fostira F, Vratimos A, Fountzilas G, Pelttari LM, Tapper WJ, Durcan L, Cross SS, Pilarski R, Shapiro CL, Klemp J, Yao S, Garber J, Cox A, Brauch H, Ambrosone C, Nevanlinna H, Yannoukakos D, Slager SL, Vachon CM, Eccles DM, Fasching PA

Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst. 2015;107(3) (Impact(2015)=11.37, Impact(2016)=12.589). Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, Hasenburg A, Sehouli J, Habermann A, Hillemanns P, Fuerst S, Strauss HG, Baumann K, Thiel F, Mustea A, Meier W, du Bois A, Griebel LF, Woelber L, AGO-CaRE 1 investigators

Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. 2015;107(5) (Impact(2015)=11.37, Impact(2016)=12.589). Mavaddat N, ..., Wang-Gohrke S, ..., Garcia-Closas M

Pre-pregnancy obesity compromises obstetric and neonatal outcomes. J Perinat Med. 2015;43(2): 141-6 (Impact(2015)=1.798, Impact(2016)=1.577). Hancke K, Gundelach T, Hay B, Sander S, Reister F, Weiss JM

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015;313(13): 1347-61 (Impact(2015)=37.684, Impact(2016)=44.405). Rebbeck TR, ..., Wang-Gohrke S, ..., Andrulis I

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001): 1341-52 (Impact(2015)=44.002, Impact(2016)=47.831). Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , ..., Janni W, ..., Llombart HA

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386(10001): 1353-61 (Impact(2015)=44.002, Impact(2016)=47.831). Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , ..., Janni W, ..., Llombart HA

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8): 928-36 (Impact(2015)=26.509, Impact(2016)=33.9). Oza AM, ..., Kreienberg R, ..., Johnson P

NF-?B-dependent DNA damage-signaling differentially regulates DNA double-strand break repair mechanisms in immature and mature human hematopoietic cells. Leukemia. 2015;29(7): 1543-54 (Impact(2015)=12.104, Impact(2016)=11.702). Kraft D, Rall M, Volcic M, Metzler E, Groo A, Stahl A, Bauer L, Nasonova E, Salles D, Taucher-Scholz G, Bönig H, Fournier C, Wiesmüller L

Role of lamin b1 in chromatin instability. Mol Cell Biol. 2015;35(5): 884-98 (Impact(2015)=4.427, Impact(2016)=4.398). Butin-Israeli V, Adam SA, Jain N, Otte GL, Neems D, Wiesmuller L, Berger SL, Goldman RD

Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nat Commun. 2015;6: 8234 (Impact(2015)=11.329, Impact(2016)=12.124). Lawrenson K, ..., Wang-Gohrke S, ..., Freedman ML

Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2015;48(1): 101 (Impact(2015)=31.616, Impact(2016)=27.959). Bolton KL, ..., Wang-Gohrke S, ..., Gayther SA

Genome-wide significant risk associations for mucinous ovarian carcinoma. Nat Genet. 2015;47(8): 888-97 (Impact(2015)=31.616, Impact(2016)=27.959). Kelemen LE, ..., Wang-Gohrke S, ..., Gertig D

Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015;47(2): 164-71 (Impact(2015)=31.616, Impact(2016)=27.959). Kuchenbaecker KB, ..., Wang-Gohrke S, ..., Young MA

ATM-dependent phosphorylation of MRE11 controls extent of resection during homology directed repair by signalling through Exonuclease 1. Nucleic Acids Res. 2015;43(17): 8352-67 (Impact(2015)=9.202, Impact(2016)=10.162). Kijas AW, Lim YC, Bolderson E, Cerosaletti K, Gatei M, Jakob B, Tobias F, Taucher-Scholz G, Gueven N, Oakley G, Concannon P, Wolvetang E, Khanna KK, Wiesmüller L, Lavin MF

Endonuclease G initiates DNA rearrangements at the MLL breakpoint cluster upon replication stress. Oncogene. 2015;34(26): 3391-401 (Impact(2015)=7.932, Impact(2016)=7.519). Gole B, Baumann C, Mian E, Ireno CI, Wiesmüller L

Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. Oncotarget. 2015;6(30): 30072-87 (Impact(2015)=5.008, Impact(2016)=5.168). Caiola E, Salles D, Frapolli R, Lupi M, Rotella G, Ronchi A, Garassino MC, Mattschas N, Colavecchio S, Broggini M, Wiesmüller L, Marabese M

The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. Oncotarget. 2015;6(10): 7390-407 (Impact(2015)=5.008, Impact(2016)=5.168). Fagerholm R, Schmidt MK, Khan S, Rafiq S, Tapper W, Aittomäki K, Greco D, Heikkinen T, Muranen TA, Fasching PA, Janni W, Weinshilboum R, Loehberg CR, Hopper JL, Southey MC, Keeman R, Lindblom A, Margolin S, Mannermaa A, Kataja V, Chenevix-Trench G, kConFab Investigators , Lambrechts D, Wildiers H, Chang-Claude J, Seibold P, Couch FJ, Olson JE, Andrulis IL, Knight JA, García-Closas M, Figueroa J, Hooning MJ, Jager A, Shah M, Perkins BJ, Luben R, Hamann U, Kabisch M, Czene K, Hall P, Easton DF, Pharoah PD, Liu J, Eccles D, Blomqvist C, Nevanlinna H

Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients. Oncotarget. 2015;6(15): 13387-401 (Impact(2015)=5.008, Impact(2016)=5.168). Stückrath I, Rack B, Janni W, Jäger B, Pantel K, Schwarzenbach H

Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. PLoS ONE. 2015;10(4): e0120020 (Impact(2015)=3.057, Impact(2016)=2.806). Blanco I, ..., Wang-Gohrke S, ..., Borg Å

Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE. 2015;10(6): e0128106 (Impact(2015)=3.057, Impact(2016)=2.806). Chornokur G, ..., Wang-Gohrke S, ..., Phelan CM

Determinants of maternal hair cortisol concentrations at delivery reflecting the last trimester of pregnancy. Psychoneuroendocrinology. 2015;52: 289-96 (Impact(2015)=4.704, Impact(2016)=4.788). Braig S, Grabher F, Ntomchukwu C, Reister F, Stalder T, Kirschbaum C, Genuneit J, Rothenbacher D

Regulation of endothelial permeability in the primate corpora lutea: implications for ovarian hyperstimulation syndrome. Reproduction. 2015;149(2): R71-R79 (Impact(2015)=3.184, Impact(2016)=3.1). Herr D, Bekes I, Wulff C

Estrogen Receptor and HER2 Status on Disseminated Tumor Cells and Primary Tumor in Patients with Early Breast Cancer. Transl Oncol. 2015;8(6): 509-16 (Impact(2016)=3.025). Jäger BA, Finkenzeller C, Bock C, Majunke L, Jueckstock JK, Andergassen U, Neugebauer JK, Pestka A, Friedl TW, Jeschke U, Janni W, Doisneau-Sixou SF, Rack BK

Predicting fatigue in older breast cancer patients receiving radiotherapy. A head-to-head comparison of established assessments. Z Gerontol Geriatr. 2015;48(2): 128-34 (Impact(2015)=0.769, Impact(2016)=0.885). Denkinger MD, Hasch M, Gerstmayer A, Kreienberg R, Nikolaus T, Hancke K

COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. Ann Oncol. 2014;25(2): 372-7 (Impact(2014)=7.04, Impact(2016)=11.855). Hadji P, Jackisch C, Bolten W, Blettner M, Hindenburg HJ, Klein P, König K, Kreienberg R, Rief W, Wallwiener D, Zaun S, Harbeck N

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol. 2014;25(8): 1551-7 (Impact(2014)=7.04, Impact(2016)=11.855). Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W

Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. Ann Oncol. 2014;25(7): 1320-7 (Impact(2014)=7.04, Impact(2016)=11.855). Trillsch F, Mahner S, Woelber L, Vettorazzi E, Reuss A, Ewald-Riegler N, de Gregorio N, Fotopoulou C, Schmalfeldt B, Burges A, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Kommoss F, Hauptmann S, du Bois A

The impact of adjuvant radiotherapy on the survival of primary breast cancer patients: a retrospective multicenter cohort study of 8935 subjects. Ann Oncol. 2014;25(3): 628-32 (Impact(2014)=7.04, Impact(2016)=11.855). Wöckel A, Wolters R, Wiegel T, Novopashenny I, Janni W, Kreienberg R, Wischnewsky M, Schwentner L, BRENDA study group , Gnauert K, Fritz S, Goretzlehner U, Vollert HW, Albert PJ, Felberbaum R, Zorr A, Flock F, Schlicht E, Gropp-Meier M, Bartzke G, Rempen A, Schelble E, Dinkelacker T, Gruneberger A, Kuhn T

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)+. Ann Oncol. 2014;25(12): 2363-72 (Impact(2014)=7.04, Impact(2016)=11.855). von Minckwitz G, ..., Huober J, ..., Janni W, ..., Schlag R

eNOSI4 and EPHX1 polymorphisms affect maternal susceptibility to preeclampsia: analysis of five polymorphisms predisposing to cardiovascular disease in 279 Caucasian and 241 African women. Arch Gynecol Obstet. 2014;289(3): 581-93 (Impact(2014)=1.364, Impact(2016)=2.09). Groten T, Schleussner E, Lehmann T, Reister F, Holzer B, Danso KA, Zeillinger R

Work-life balance of German gynecologists: a web-based survey on satisfaction with work and private life. Arch Gynecol Obstet. 2014;289(1): 123-9 (Impact(2014)=1.364, Impact(2016)=2.09). Hancke K, Igl W, Toth B, Bühren A, Ditsch N, Kreienberg R

Fluorescence-based recombination assay for sensitive and specific detection of genotoxic carcinogens in human cells. Arch Toxicol. 2014;88(5): 1141-59 (Impact(2014)=5.98, Impact(2016)=5.901). Ireno IC, Baumann C, Stöber R, Hengstler JG, Wiesmüller L

FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. BMC Cancer. 2014;14: 66 (Impact(2014)=3.362, Impact(2016)=3.288). Fasching PA, Jud SM, Hauschild M, Kümmel S, Schütte M, Warm M, Hanf V, Grab D, Krocker J, Stickeler E, Kreienberg R, Müller T, Kühn T, Wolf C, Kahlert S, Paepke S, Berghorn M, Muth M, Baier M, Wackwitz B, Schulz-Wendtland R, Beckmann MW, Lux MP

Evaluation of two different analytical methods for circulating tumor cell detection in peripheral blood of patients with primary breast cancer. Biomed Res Int. 2014;2014: 491459 (Impact(2014)=1.579, Impact(2016)=2.476). Jaeger BA, Jueckstock J, Andergassen U, Salmen J, Schochter F, Fink V, Alunni-Fabbroni M, Rezai M, Beck T, Beckmann MW, Friese K, Friedl TW, Janni W, Rack B

The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the Compliance of ARomatase Inhibitors AssessmenT In Daily practice through Educational approach (CARIATIDE) study. Breast. 2014;23(4): 393-9 (Impact(2014)=2.381, Impact(2016)=2.801). Neven P, Markopoulos C, Tanner M, Marty M, Kreienberg R, Atkins L, Franquet A, Gnant M, Neciosup S, Tesarova P, Barni S, Deschamp V

International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Res. 2014;16(2): R43 (Impact(2014)=5.49, Impact(2016)=6.345). Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothé F, Metallo J, Rouas G, Payne RE, Coombes R, Teufel I, Andergassen U, Apostolaki S, Politaki E, Mavroudis D, Bessi S, Pestrin M, Di Leo A, Campion M, Reinholz M, Perez E, Piccart M, Borgen E, Naume B, Jimenez J, Aura C, Zorzino L, Cassatella M, Sandri M, Mostert B, Sleijfer S, Kraan J, Janni W, Fehm T, Rack B, Terstappen L, Repollet M, Pierga JY, Miller C, Sotiriou C, Michiels S, Pantel K

Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat. 2014;143(1): 159-69 (Impact(2014)=3.94, Impact(2016)=3.626). Huober J, Cole BF, Rabaglio M, Giobbie-Hurder A, Wu J, Ejlertsen B, Bonnefoi H, Forbes JF, Neven P, Láng I, Smith I, Wardley A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Gelber RD, Thürlimann B, BIG 1-98 Collaborative and International Breast Cancer Study Groups

A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2014;143(3): 493-505 (Impact(2014)=3.94, Impact(2016)=3.626). Janni W, Sarosiek T, Karaszewska B, Pikiel J, Staroslawska E, Potemski P, Salat C, Brain E, Caglevic C, Briggs K, Desilvio M, Marini L, Papadimitriou C

Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res Treat. 2014;144(1): 153-62 (Impact(2014)=3.94, Impact(2016)=3.626). Loibl S, Volz C, Mau C, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Hanusch C, Jackisch C, Kümmel S, Huober J, Denkert C, Hilfrich J, Konecny GE, Fett W, Stickeler E, Harbeck N, Mehta KM, Nekljudova V, von Minckwitz G, Untch M

Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. Breast Cancer Res Treat. 2014;148(1): 143-51 (Impact(2014)=3.94, Impact(2016)=3.626). Salmen J, Neugebauer J, Fasching PA, Haeberle L, Huober J, Wöckel A, Rauh C, Schuetz F, Weissenbacher T, Kost B, Stickeler E, Klar M, Orlowska-Volk M, Windfuhr-Blum M, Heil J, Rom J, Sohn C, Fehm T, Mohrmann S, Loehberg CR, Hein A, Schulz-Wendtland R, Hartkopf AD, Brucker SY, Wallwiener D, Friese K, Hartmann A, Beckmann MW, Janni W, Rack B

Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells? Breast Care (Basel). 2014;9(1): 16-21 (Impact(2014)=0.627, Impact(2016)=1.553). Alunni-Fabbroni M, Müller V, Fehm T, Janni W, Rack B

Should a drain be placed in early breast cancer surgery? Breast Care (Basel). 2014;9(2): 116-22 (Impact(2014)=0.627, Impact(2016)=1.553). Ebner F, deGregorio N, Vorwerk E, Janni W, Wöckel A, Varga D

Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective. Breast Care (Basel). 2014;9(1): 52-9 (Impact(2014)=0.627, Impact(2016)=1.553). Harbeck N, Marschner N, Untch M, Decker T, Hegewisch-Becker S, Jackisch C, Huober J, Lück HJ, von Minckwitz G, Scharl A, Schneeweiss A, Tesch H, Welt A, Wuerstlein R, Thomssen C

Bone Targeted Therapy in Breast Cancer - an Old Concept but Still Much to Do. Breast Care (Basel). 2014;9(5): 310-310 (Impact(2014)=0.627, Impact(2016)=1.553). Huober J, Thurlimann B

Adjuvant therapy in breast cancer - have we already learned the entire lesson? Breast Care (Basel). 2014;9(3): 153 (Impact(2014)=0.627, Impact(2016)=1.553). Janni W

Risk of Ovarian Cancer and the NF-?B Pathway: Genetic Association with IL1A and TNFSF10. Cancer Res. 2014;74(3): 852-61 (Impact(2014)=9.329, Impact(2016)=9.122). Charbonneau B, ..., Wang-Gohrke S, ..., Goode EL

Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53. Carcinogenesis. 2014;35(10): 2273-82 (Impact(2014)=5.334, Impact(2016)=5.105). Ireno IC, Wiehe RS, Stahl AI, Hampp S, Aydin S, Troester MA, Selivanova G, Wiesmüller L

Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis. 2014;35(5): 1012-9 (Impact(2014)=5.334, Impact(2016)=5.105). Purrington KS, ..., Janni W, ..., Scholz C, ..., Couch FJ

Parachuting and pregnancy: what do we know about pregnant skydivers and the risks they are taking? Clin J Sport Med. 2014;24(6): 468-73 (Impact(2014)=2.268, Impact(2016)=2.189). Ebner F, Wöckel A, Janni W, Paterson H

Sentinel node biopsy and axillary dissection in breast cancer: the evidence and its limits. Dtsch Arztebl Int. 2014;111(14): 244-9 (Impact(2014)=3.518, Impact(2016)=4.257). Janni W, Kühn T, Schwentner L, Kreienberg R, Fehm T, Wöckel A

Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677. Eur J Cancer. 2014;50(17): 2905-15 (Impact(2014)=5.417, Impact(2016)=6.029). Schwentner L, Wöckel A, König J, Janni W, Blettner M, Kreienberg R, Van Ewijk R, BRENDA study group , Gnauert K, Fritz S, Göretzlehner U, Vollert HW, Albert PJ, Felberbaum R, Zorr A, Flock F, Schlicht E, Gropp-Meier M, Bartzke G, Rempen A, Schelble E, Dinkelacker T, Gru A, Kühn T

Compartment syndrome after gynecologic operations: evidence from case reports and reviews. Eur J Obstet Gynecol Reprod Biol. 2014;173: 7-12 (Impact(2014)=1.695, Impact(2016)=1.666). Bauer EC, Koch N, Janni W, Bender HG, Fleisch MC

Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients. Future Oncol. 2014;10(10): 1751-65 (Impact(2014)=2.477, Impact(2016)=2.131). Bock C, Rack B, Huober J, Andergassen U, Jeschke U, Doisneau-Sixou S

DGGG Guidelines Programme: Status Quo - Quo Vadis! Geburtshilfe Frauenheilkd. 2014;74(3): 251-259 (Impact(2014)=0.936, Impact(2016)=1.07). Beckmann MW, Linde I, Bütof C, Kreienberg R, Gass P

Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study. Geburtshilfe Frauenheilkd. 2014;74(12): 1137-1143 (Impact(2014)=0.936, Impact(2016)=1.07). Fasching PA, Fehm T, Kellner S, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Würstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesslet T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauß T, Thomssen C, Kümmel S, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Hadji P, Wallwiener D, Grischke EM, Beckmann MW, Brucker SY

On the death of Prof. Dr. med Volker Friedberg. Geburtshilfe Frauenheilkd. 2014;74(6): 538-539 (Impact(2014)=0.936, Impact(2016)=1.07). Hepp H, Kreienberg R

"Pregnant and Operating": Evaluation of a Germany-wide Survey Among Female Gynaecologists and Surgeons. Geburtshilfe Frauenheilkd. 2014;74(9): 875-880 (Impact(2014)=0.936, Impact(2016)=1.07). Knieper C, Ramsauer B, Hancke K, Woeckel A, Ismail L, Bühren A, Toth B

Circulating Tumor Cells in metastatic Breast Cancer. Geburtshilfe Frauenheilkd. 2014;74(11): 986-988 (Impact(2014)=0.936, Impact(2016)=1.07). Krawczyk N, Meier-Stiegen F, Katzorke N, Janni W, Muller V, Rack B, Fasching P, Wallwiener D, Albrecht S, Fehm T

Strategies for Orientation in Literature-Jungle Camp. Geburtshilfe Frauenheilkd. 2014;74(3): 205-207 (Impact(2014)=0.936, Impact(2016)=1.07). Schwentner L, Janni W

Methodology and Results Foundation for a solid Publication Construction Site. Geburtshilfe Frauenheilkd. 2014;74(6): 535-536 (Impact(2014)=0.936, Impact(2016)=1.07). Schwentner L, Janni W

The appropriate Framework: Introduction and Discussion. Geburtshilfe Frauenheilkd. 2014;74(9): 817-819 (Impact(2014)=0.936, Impact(2016)=1.07). Schwentner L, Janni W

Concentration of gynaecology and obstetrics in Germany: Is comprehensive access at stake? Health Policy. 2014;118(3): 396-406 (Impact(2014)=1.907, Impact(2016)=2.119). Mennicken R, Kolodziej IW, Augurzky B, Kreienberg R

Assisted reproductive technology in Europe, 2010: results generated from European registers by ESHRE+. Hum Reprod. 2014;29(10): 2099-113 (Impact(2014)=4.569, Impact(2016)=5.02). Kupka MS, ..., Hancke K, Seemann B, ..., Rosenbusch B, ..., Mulfinger L

Presence of disseminated tumor cells in bone marrow correlates with tumor stage and nodal involvement in cervical cancer patients. Int J Cancer. 2014;134(4): 925-31 (Impact(2014)=5.085, Impact(2016)=6.513). Fehm T, Banys M, Rack B, Jäger B, Hartkopf A, Taran FA, Janni W

Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients. Int J Cancer. 2014;134(7): 1725-33 (Impact(2014)=5.085, Impact(2016)=6.513). Hilvo M, Gade S, Hyötyläinen T, Nekljudova V, Seppänen-Laakso T, Sysi-Aho M, Untch M, Huober J, von Minckwitz G, Denkert C, Ore?i? M, Loibl S

Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer. Int J Cancer. 2014;135(10): 2352-61 (Impact(2014)=5.085, Impact(2016)=6.513). Kast K, Schmutzler RK, Rhiem K, Kiechle M, Fischer C, Niederacher D, Arnold N, Grimm T, Speiser D, Schlegelberger B, Varga D, Horvath J, Beer M, Briest S, Meindl A, Engel C

Fertility preservation after caesarean delivery in a woman diagnosed with Morbus Hodgkin disease during pregnancy. J Assist Reprod Genet. 2014;31(1): 51-3 (Impact(2014)=1.718, Impact(2016)=2.163). Gundelach T, Stuck D, Widschwendter P, Weiss JM, Janni W, Hancke K

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
J Clin Oncol. 2014;32(29): 3212-20 (Impact(2014)=18.443, Impact(2016)=24.008). Loibl S, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, Sinn P, Khandan F, Eidtmann H, Dohnal K, Heinrichs C, Huober J, Pfitzner B, Fasching PA, Andre F, Lindner JL, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Denkert C

Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014;32(13): 1309-16 (Impact(2014)=18.443, Impact(2016)=24.008). Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E

Response.
J Natl Cancer Inst. 2014;106(3): djt452 (Impact(2014)=12.583, Impact(2016)=12.589). Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz UA, Runnebaum IB, Hinke A, Kreienberg R, Untch M, AGO Breast Study Group

Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014;106(5) (Impact(2014)=12.583, Impact(2016)=12.589). Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, Friedl TW, Lorenz R, Tesch H, Fasching PA, Fehm T, Schneeweiss A, Lichtenegger W, Beckmann MW, Friese K, Pantel K, Janni W, SUCCESS Study Group

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.
Lancet. 2014;383(9935): 2127-35 (Impact(2014)=45.217, Impact(2016)=47.831). EBCTCG (Early Breast Cancer Trialists' Collaborative Group) , ..., Kreienberg R, ..., Janni W, ..., Caffier H

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014;15(4): 406-14 (Impact(2014)=24.69, Impact(2016)=33.9). Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7): 747-56 (Impact(2014)=24.69, Impact(2016)=33.9). von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kümmel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M

Survey of compartment syndrome of the lower extremity after gynecological operations. Langenbecks Arch Surg. 2014;399(3): 343-8 (Impact(2014)=2.191, Impact(2016)=2.203). Bauer EC, Koch N, Erichsen CJ, Juettner T, Rein D, Janni W, Bender HG, Fleisch MC

NuMA promotes homologous recombination repair by regulating the accumulation of the ISWI ATPase SNF2h at DNA breaks. Nucleic Acids Res. 2014;42(10): 6365-79 (Impact(2014)=9.112, Impact(2016)=10.162). Vidi PA, Liu J, Salles D, Jayaraman S, Dorfman G, Gray M, Abad P, Moghe PV, Irudayaraj JM, Wiesmüller L, Lelièvre SA

Benefits and risks of breast cancer screening. Oncol Res Treat. 2014;37 Suppl 3: 21-8 (Impact(2014)=0, Impact(2016)=1.667). Wöckel A, Janni W, Porzsolt F, Schmutzler R

DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. 2014;10(4): e1004256 (Impact(2014)=7.528, Impact(2016)=6.1)
Osorio A, ..., Wang-Gohrke S, ..., Benitez J

Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers. Virchows Arch. 2014;465(3): 365-9 (Impact(2014)=2.651, Impact(2016)=2.848). Gevensleben H, Bossung V, Meindl A, Wappenschmidt B, de Gregorio N, Osorio A, Romero A, Buettner R, Markiefka B, Schmutzler RK

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol. 2013;24(12): 2978-84 (Impact(2013)=6.578, Impact(2016)=11.855). Gerber B, Loibl S, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Nekljudova V, Untch M, von Minckwitz G, German Breast Group Investigators

The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol. 2013;24(6): 1505-12 (Impact(2013)=6.578, Impact(2016)=11.855). Hadji P, Blettner M, Harbeck N, Jackisch C, Lück HJ, Windemuth-Kieselbach C, Zaun S, Kreienberg R

Spermatozoa vitrification of sex-reversed rainbow trout (Oncorhynchus mykiss): Effect of seminal plasma on physiological parameters. Aquaculture. 2013;372: 119-126 (Impact(2013)=1.828, Impact(2016)=2.57). Figueroa E, Risopatron J, Sanchez R, Isachenko E, Merino O, Isachenko V, Valdebenito I

A lost LNG-IUP in the bladder. Arch Gynecol Obstet. 2013;287(5): 1055-6 (Impact(2013)=1.279, Impact(2016)=2.09). Ebner F, Petirsch O, Rempen A

Trends in patient characteristics, treatment and survival in breast cancer in a non-selected retrospective clinical cohort study of 2,600 patients. Arch Gynecol Obstet. 2013;287(1): 103-10 (Impact(2013)=1.279, Impact(2016)=2.09). Van Ewijk RJ, Schwentner L, Wöckel A, König J, Kreienberg R, Blettner M, BRENDA study group

Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC Cancer. 2013;13: 480 (Impact(2013)=3.319, Impact(2016)=3.288). Banys M, Solomayer EF, Gebauer G, Janni W, Krawczyk N, Lueck HJ, Becker S, Huober J, Kraemer B, Wackwitz B, Hirnle P, Wallwiener D, Fehm T

Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9156 patients. BMC Cancer. 2013;13: 487 (Impact(2013)=3.319, Impact(2016)=3.288). Schwentner L, Wöckel A, König J, Janni W, Ebner F, Blettner M, Kreienberg R, Van Ewijk R

Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Res Treat. 2013;139(3): 779-87 (Impact(2013)=4.198, Impact(2016)=3.626). Lück HJ, Du Bois A, Loibl S, Schrader I, Huober J, Heilmann V, Beckmann M, Stähler A, Jackisch C, Hubalek M, Richter B, Stickeler E, Eidtmann H, Thomssen C, Untch M, Wollschläger K, Schuster T, von Minckwitz G

The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat. 2013;137(2): 503-10 (Impact(2013)=4.198, Impact(2016)=3.626). Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K, Marmé F, Sohn C, Trumpp A, Rack B, Aktas B, Solomayer EF, Müller V, Janni W, Schneeweiss A, Fehm TN

Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients. Breast Cancer Res Treat. 2013;142(3): 579-90 (Impact(2013)=4.198, Impact(2016)=3.626). Wolters R, Wöckel A, Janni W, Novopashenny I, Ebner F, Kreienberg R, Wischnewsky M, Schwentner L, BRENDA Study Group

Circulating Tumor Cells in Diagnosis and Treatment of Breast Cancer. Breast Care (Basel). 2013;8(5): 375-377 (Impact(2013)=0.911, Impact(2016)=1.553). Fehm T, Hartkopf A, Janni W, Solomayer E, Rack B, Muller V

Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breas. Breast Care (Basel). 2013;8(2): 110-20 (Impact(2013)=0.911, Impact(2016)=1.553). Harbeck N, Blettner M, Hadji P, Jackisch C, Lück HJ, Windemuth-Kieselbach C, Zaun S, Haidinger R, Schmitt D, Schulte H, Nitz U, Kreienberg R

Patient-centered additional offers in breast centers. Breast Care (Basel). 2013;8(5): 329 (Impact(2013)=0.911, Impact(2016)=1.553). Janni W, Hanf V

Side Effects of Standard Adjuvant and Neoadjuvant Chemotherapy Regimens According to Age Groups in Primary Breast Cancer. Breast Care (Basel). 2013;8(1): 60-66 (Impact(2013)=0.911, Impact(2016). 1.553). Reinisch M, von Minckwitz G, Harbeck N, Janni W, Kummel S, Kaufmann M, Elling D, Nekljudova V, Loibl S

13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013). Breast Care (Basel). 2013;8(3): 221-9 (Impact(2013)=0.911, Impact(2016)=1.553). Untch M, Gerber B, Harbeck N, Jackisch C, Marschner N, Möbus V, von Minckwitz G, Loibl S, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Dimpfl T, Eiermann W, Fehm T, Friese K, Jänicke F, Janni W, Jonat W, Kiechle M, Köhler U, Lück HJ, Maass N, Possinger K, Rody A, Scharl A, Schneeweiss A, Thomssen C, Wallwiener D, Welt A

Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res. 2013;73(8): 2468-79 (Impact(2013)=9.284, Impact(2016)=9.122). Lindner S, Dahlke K, Sontheimer K, Hagn M, Kaltenmeier C, Barth TF, Beyer T, Reister F, Fabricius D, Lotfi R, Lunov O, Nienhaus GU, Simmet T, Kreienberg R, Möller P, Schrezenmeier H, Jahrsdörfer B

Risk awareness and transparency. Dtsch Arztebl Int. 2013;110(16): 286-7 (Impact(2013)=3.608, Impact(2016)=4.257). Kreienberg R, Kopp IB

Prospective risk factor monitoring reduces intracranial hemorrhage rates in preterm infants. Dtsch Arztebl Int. 2013;110(29-30): 489-96 (Impact(2013)=3.608, Impact(2016)=4.257). Schmid MB, Reister F, Mayer B, Hopfner RJ, Fuchs H, Hummler HD

Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer. 2013;20(2): 251-62 (Impact(2013)=4.907, Impact(2016)=5.267). Olsen CM, ..., Wang-Gohrke S, ..., Pavlakis N

German, Austrian and Swiss consensus conference on the diagnosis and local treatment of the axilla in breast cancer. Eur J Cancer. 2013;49(10): 2277-83 (Impact(2013)=4.819, Impact(2016)=6.029). AGO , DGS , SGS , ÖGS , Panelists , Executive Board Members , ..., Janni W, ..., Markus Z

Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: A systematic review and meta-analysis. Eur J Cancer. 2013;49(4): 812-25 (Impact(2013)=4.819, Impact(2016)=6.029). Glechner A, Wöckel A, Gartlehner G, Thaler K, Strobelberger M, Griebler U, Kreienberg R

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer. 2013;49(8): 1825-35 (Impact(2013)=4.819, Impact(2016)=6.029). Harbeck N, ..., Kreienberg R, ..., Geurts-Moespot A

Participation in adjuvant clinical breast cancer trials: does study participation improve survival compared to guideline adherent adjuvant treatment? A retrospective multi-centre cohort study of 9,433 patients. Eur J Cancer. 2013;49(3): 553-63 (Impact(2013)=4.819, Impact(2016)=6.029). Schwentner L, Van Ewijk R, Kurzeder C, Hoffmann I, König J, Kreienberg R, Blettner M, Wöckel A

Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Eur J Cancer. 2013;49(8): 1905-14 (Impact(2013)=4.819, Impact(2016)=6.029). du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss S, Hauptmann S, Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group

VEGF but not PlGF disturbs the barrier of retinal endothelial cells. Exp Eye Res. 2013;115: 162-71 (Impact(2013)=3.017, Impact(2016)=3.332). Deissler HL, Deissler H, Lang GK, Lang GE

Human chorionic gonadotropin controls luteal vascular permeability via vascular endothelial growth factor by down-regulation of a cascade of adhesion proteins. Fertil Steril. 2013;99(6): 1749-58 (Impact(2013)=4.295, Impact(2016)=4.373). Herr D, Fraser HM, Konrad R, Holzheu I, Kreienberg R, Wulff C

Local Renin-Angiotensin System in the Reproductive System. Front Endocrinol (Lausanne). 2013;4: 150 (Impact(2016)=3.675). Herr D, Bekes I, Wulff C

Participation in the SUCCESS-A Trial Improves Intensity and Quality of Care for Patients with Primary Breast Cancer. Geburtshilfe Frauenheilkd. 2013;73(1): 63-69 (Impact(2013)=0.962, Impact(2016)=1.07). Andergassen U, Kasprowicz NS, Hepp P, Schindlbeck C, Harbeck N, Kiechle M, Sommer H, Beckmann MW, Friese K, Janni W, Rack B, Scholz C, SUCCESS Study Grp

Does Non-Placement of a Drain in Breast Surgery Increase the Rate of Complications and Revisions? Geburtshilfe Frauenheilkd. 2013;73(11): 1128-1134 (Impact(2013)=0.962, Impact(2016)=1.07). Ebner FK, Friedl TWP, deGregorio N, Reich A, Janni W, Rempen A

Regulation of Endothelial Permeability in the Corpus Luteum: A Review of the Literature. Geburtshilfe Frauenheilkd. 2013;73(11): 1107-1111 (Impact(2013)=0.962, Impact(2016)=1.07). Herr D, Bekes I, Wulff C

Breast Cancer 2013 – Interpretation of New and Known Data. Geburtshilfe Frauenheilkd. 2013;73(06): 584-598 (Impact(2013)=0.962, Impact(2016)=1.07). Lux M, Maass N, Schuetz F, Schwidde I, Fasching P, Fehm T, Janni W, Kuemmel S, Kolberg H-C, Lueftner D

Identification of alternative transcripts of rat CD9 expressed by tumorigenic neural cell lines and in normal tissues. Genet Mol Biol. 2013;36(2): 276-81 (Impact(2013)=0.876, Impact(2016)=1.147). Wolfahrt S, Herman S, Scholz CJ, Sauer G, Deissler H

Ranibizumab efficiently blocks migration but not proliferation induced by growth factor combinations including VEGF in retinal endothelial cells. Graefes Arch Clin Exp Ophthalmol. 2013;251(10): 2345-53 (Impact(2013)=2.333, Impact(2016)=2.349). Deissler HL, Deissler H, Lang GK, Lang GE

The role of preoperative ultrasound evaluation of inguinal lymph nodes in patients with vulvar malignancy. Gynecol Oncol. 2013;131(1): 113-7 (Impact(2013)=3.687, Impact(2016)=4.959). de Gregorio N, Ebner F, Schwentner L, Friedl TW, Deniz M, Látó K, Kreienberg R, Janni W, Varga D

Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer. Int J Gynecol Cancer. 2013;23(5): 839-45 (Impact(2013)=1.949, Impact(2016)=2.369). Fehm T, Banys M, Rack B, Janni W, Marth C, Blassl C, Hartkopf A, Trope C, Kimmig R, Krawczyk N, Wallwiener D, Wimberger P, Kasimir-Bauer S

Ovarian cancer: in search of better marker systems based on DNA repair defects. Int J Mol Sci. 2013;14(1): 640-73 (Impact(2013)=2.339, Impact(2016)=3.226). Varga D, Deniz M, Schwentner L, Wiesmüller L

Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13). Invest New Drugs. 2013;31(6): 1499-504 (Impact(2013)=2.927, Impact(2016)=3.484). Harter P, Sehouli J, Kimmig R, Rau J, Hilpert F, Kurzeder C, Elser G, du Bois A

Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients. J Cancer Res Clin Oncol. 2013;139(6): 1055-62 (Impact(2013)=3.009, Impact(2016)=3.503). Schindlbeck C, Andergassen U, Hofmann S, Jückstock J, Jeschke U, Sommer H, Friese K, Janni W, Rack B

Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol. 2013;31(23): 2870-8 (Impact(2013)=17.96, Impact(2016)=24.008). Crown JP, Diéras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, Ramos M, Greil R, Cognetti F, Fountzilas G, Blasinska-Morawiec M, Liedtke C, Kreienberg R, Miller WH, Tassell V, Huang X, Paolini J, Kern KA, Romieu G

Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study. J Clin Oncol. 2013;31(12): 1554-61 (Impact(2013)=17.96, Impact(2016)=24.008). Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J

German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol. 2013;31(28): 3531-9 (Impact(2013)=17.96, Impact(2016)=24.008). von Minckwitz G, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, Jackisch C, Diel IJ, Elling D, Conrad B, Kreienberg R, Müller V, Lück HJ, Bauerfeind I, Clemens M, Schmidt M, Noeding S, Forstbauer H, Barinoff J, Belau A, Nekljudova V, Harbeck N, Loibl S

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst. 2013;105(14): 1018-26 (Impact(2013)=15.161, Impact(2016)=12.589). Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M, AGO Breast Study Group

Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients. Mol Oncol. 2013;7(5): 976-86 (Impact(2013)=5.935, Impact(2016)=5.314). Schneck H, Blassl C, Meier-Stiegen F, Neves RP, Janni W, Fehm T, Neubauer H

Functional analysis-make or break for cancer predictability. Mutat Res. 2013;743-744: 132-41 (Impact(2013)=4.44, Impact(2016)=1.829). Deniz M, Holzmann K, Wiesmüller L

Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun. 2013;4: 1627 (Impact(2013)=10.742, Impact(2016)=12.124). Permuth-Wey J, ..., Wang-Gohrke S, ..., Couch FJ

Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun. 2013;4: 1628 (Impact(2013)=10.742, Impact(2016)=12.124). Shen H, ..., Wang-Gohrke S, ..., Wood S

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet. 2013;45(4): 371-84, 384e1-2 (Impact(2013)=29.648, Impact(2016)=27.959). Bojesen SE, ..., Wang-Gohrke S, ..., Deissler H, ..., Dunning AM

GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet. 2013;45(4): 362-70, 370e1-2 (Impact(2013)=29.648, Impact(2016)=27.959). Pharoah PD, ..., Wang-Gohrke S, ..., Sellers TA

Cerebral near-infrared spectroscopy during transition of healthy term newborns. Neonatology. 2013;103(4): 246-51 (Impact(2013)=2.369, Impact(2016)=2.598). Almaazmi M, Schmid MB, Havers S, Reister F, Lindner W, Mayer B, Hummler HD, Fuchs H

siRNA screening identifies differences in the Fanconi anemia pathway in BALB/c-Trp53+/- with susceptibility versus C57BL/6-Trp53+/- mice with resistance to mammary tumors. Oncogene. 2013;32(48): 5458-70 (Impact(2013)=8.559, Impact(2016)=7.519). Böhringer M, Obermeier K, Griner N, Waldraff D, Dickinson E, Eirich K, Schindler D, Hagen M, Jerry DJ, Wiesmüller L

News from targeted Therapy-PI3K/AKT/mTOR-Inhibitors - Promising in advanced gynecological Tumors. Onkologe. 2013;19(3): 232-233 (Impact(2013)=0.132, Impact(2016)=0.087). Janni W, Jager B

Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013;9(3): e1003212 (Impact(2013)=8.167, Impact(2016)=6.1). Couch FJ, ..., Deissler H, ..., CIMBA

Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet. 2013;9(3): e1003284 (Impact(2013)=8.167, Impact(2016)=6.1). Nickels S, ..., Wang-Gohrke S, ..., Chang-Claude J

Breast cancer: current recommendations for pathologists on the basis of the S3 guidelines. Pathologe. 2013;34(4): 293-302; quiz 303-4 (Impact(2013)=0.635, Impact(2016)=0.509). Lebeau A, Kreipe H, Dietel M, Schlake W, Kreienberg R